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1 General Introduction 
 
 
1.1 The immune system – an overview 
 
During evolution the immune system developed into a highly effective network to 
prevent higher organisms from severe damage caused by pathogens, e.g. viruses, 
bacteria, fungi and other parasites. Due to a complex system of humoral and cellular 
defence mechanisms the immune system is able to discriminate between self and 
non-self antigens. The defence mechanism or the so-called immune response can be 
subdivided into two different principles interacting with each other - the innate and the 
adaptive immunity. The function of the innate immunity is based on the recognition of 
pathogen-associated molecular patterns (PAMPs) by preformed receptors and 
effector cells. The components of an innate immune response are inflammatory cells 
such as macrophages and neutrophils, natural killer cells (NK cells), γ:δ T cells, B-1 
B cells and the complement system. As these components are constitutively present 
in the body the innate immune response provides a first line of defence for the 
organism controlling infections in the first four days before an initial adaptive immune 
response takes place. However, the innate immunity is inflexible using receptors with 
restricted diversity and it does not generate an immunological memory. 
Adaptive immunity also known as acquired immune response is based on clonal 
selection of antigen-specific effector lymphocytes [1; 2] and on the generation of 
memory cells to prevent reinfection. Furthermore, this system is able to respond to 
high numbers of foreign antigens using receptors whose specificities do not have to 
be genetically encoded. The adaptive immune response is characterized by the 
humoral immunity (latin: umor – moisture, fluid) and the cellular immunity. Humoral 
immunity can protect against extracellular antigens and toxins providing antibodies 
which are secreted by B lymphocytes activated by antigen-specific T helper cells 
(TH2). Cellular immunity protects from intracellular pathogens (viruses, intracellular 
bacteria) and tumors and is mainly based on cytotoxic T lymphocytes (CTLs) and 
inflammatory TH1 cells. Activation of CTLs depends on interaction with professional 
antigen-presenting cells (APCs), most notably dendritic cells (DCs) and TH1 cells 
(Figure 1). After interaction by pathogenic structures with PAMP-receptors on the 
surface, DCs become activated and are able to take up antigen in the periphery, 
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travel to peripheral immune organs and present antigen on MHC molecules to T 
cells. Therefore, one may say that DCs lie at the interface between innate and 
adaptive immunity. 
To encounter the dangers of daily life in form of viruses, bacteria, fungi and other 
parasites, the immune system is facilitated with a great variety of different 
mechanism of defense. These, unfortunately, come along with the risk for various 
malfunctions, e.g. allergy, autoimmune diseases or tumor development. For this 
purpose the major aim of research is to achieve a better and more detailed 
understanding of the immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Dendritic cells take up antigens in peripheral tissues, become matured and migrate to 
draining lymphnodes. After processing of the antigen dendritic cells express MHC/peptide-complexes 
and co-stimulatory molecules. In the lymphnodes T cells are primed and B cells are activated after 
contact with antigen presenting DCs leading to initiation of an adaptive immune response.  
 
 
J. Banchereau et al., Nature Reviews Immunology, 2005 (www.nature.com/reviews/immunol) 
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1.2 Major histocompatibility complex molecules and antigen 
processing 
 
T lymphocytes recognize antigens presented on major histocompatibility complex 
(MHC) molecules [3] found on the surface of all nucleated cells. MHC molecules - 
called human leukocyte antigens (HLA) in humans - are encoded by a large, highly 
polymorphic gene cluster on chromosome six in humans, which is usually divided into 
a class I, II, and III antigenic region. MHC class I molecules are heterodimers 
composed of a heavy α-chain which is non-covalently linked to β2-microglobulin 
(β2m). The α-chain has a short cytoplasmic C-terminal part, a transmembrane 
domain and three extracellular domains (α1-α3). The two N-terminal domains α1-α2 
form a peptide binding groove which is closed at both ends and accommodates the 
presented peptide with a length of 8-10 amino acids. Non-covalent hydrophobic and 
ionic interactions between the peptide and the α-chain mainly take place between so-
called pockets in the α1-domain and the anchor amino acids of the ligand and involve 
the N- and C-termini of the peptide.  
MHC class I molecules present peptides generated by normal cellular degradation of 
endogenously occurring proteins [4]. A large multienzyme complex - called ubiquitin-
proteasome - generates precursor peptides that have a correct C-terminus and may 
have N-terminal extensions of several amino acids [5] which are further trimmed by 
aminopeptidases found either in the cytosol [6] or in the endoplasmic reticulum (ER) 
[7]. The 20S core proteasome with its three constitutive proteolytic subunits (δ/Y, Z 
and X) shows three different proteolytical activities: a chymotrypsin-like (cleavage 
after hydrophobic residues), a trypsin-like (cleavage after basic residues) and a 
caspase-like (cleavage after acidic residues) [8]. In the presence of interferon γ 
(IFNγ) the constitutive proteasome can be converted into immunoproteasome by 
exchange of the subunits (δ/Y, Z and X) which harbor the active sites by 
immunosubunits called MECL1, LMP2 and LMP7 [9]. The newly formed 
immunoproteasome is able to enhance the generation of peptides presented on MHC 
class I [10]. The peptides generated are transported into the ER using the transporter 
associated with antigen processing (TAP) [11]. In the ER MHC I heavy chain-β2m 
heterodimers are loaded with peptides through interactions in the peptide-loading 
complex which consists additionally of the transmembrane glycoprotein tapasin, the 
chaperone calreticulin and the thiol oxidoreductase ERp57 [12]. The accumulated 
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MHC I heavy chain, β2m and peptide complexes are then transported to the cell 
surface where they interact with CD8+ T cells.  
The structure of MHC class II molecules, in humans HLA-DR, -DQ, -DP, overall 
strongly resembles class I, although it consists of two polymorphic membrane-
spanning chains, the α-chain and the β-chain with two domains each. In contrast to 
MHC class I molecules, the peptide binding groove is open at both ends what allows 
binding of longer peptides with 10-15 amino acids. MHC class II molecules present 
peptides from exogenous proteins acquired by endocytosis or from internalized 
plasma membrane proteins to CD4+ T cells. Processing of exogenous antigens and 
peptide loading take place in the same compartment in contrast to the MHC class I 
processing pathway. MHC class II α- and β-chains are synthesized into the ER and 
transported in association with the trimeric invariant chain (li) to the MHC class II 
loading compartment. There, the class II-associated invariant-chain peptide (CLIP), a 
part of the invariant chain which occupies the peptide binding groove of the MHC 
class II molecules, is replaced by the later presented peptides. This exchange is 
catalyzed and regulated by HLA-DM and HLA-DO [13].  
Recapitulating, in a classical view, MHC class I molecules present peptides from 
intracellular source proteins, whereas MHC class II molecules present antigenic 
peptides from exogenous and membrane proteins (Figure 2). However, alternative 
pathways for delivering peptides have been described. It is known that MHC class I 
molecules are able to present peptides derived from exogenous antigens by a 
process called cross presentation [14]. Intracellular proteins, in contrast, can be 
presented by MHC class II molecules [15]. It was shown that autophagy plays a role 
in the MHC class II-restricted presentation of peptides from intracellular proteins [16]. 
Autophagy is the degradation of intracellular components in lysosomes and is 
therefore relevant in the endosomal/lysosomal degradation pathway.  
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Figure 2. (A) Defective proteins in the cytosol are degraded into peptides in proteasomes. A vast 
majority of proteins are degraded by proteasomes shortly after their synthesis, presumably due in 
large part to their inability to achieve a functional state. These polypeptides are termed defective 
ribosomal products (DRiPs). Peptides are transported into the ER, where they are loaded onto newly 
synthesized class I molecules. The HLA–peptide complexes are exported by way of the Golgi 
apparatus to the surface of the cell. (B) shows the processing of extracellular proteins. Self or foreign 
proteins are taken up by endocytosis (or phagocytosis) and sequestered into endosomes. Class II 
molecules synthesized in the endoplasmic reticulum are delivered by way of the Golgi apparatus into 
primary lysosomes, which fuse with the early endosomes to form the major-histocompatibility-complex 
(MHC) class II compartment. Enzymes brought into this compartment by the lysosomes degrade the 
engulfed proteins into peptides. HLA-DM molecules synthesized in the endoplasmic reticulum and 
delivered into the MHC class II compartment by transport vesicles help load the peptides onto the 
class II molecules. Additionally, peptides can also derive from intracellular antigens, which can be 
presented on MHC class II molecules through autophagy. The HLA–peptide complexes are then 
exported to the surface of the cell.  
 
www.hallym.or.kr/.../ immunogenetics/NEJM-HLA.htm 
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1.3 T lymphocytes 
 
Early in development, T lymphocytes are able to differentiate in T cells expressing αβ 
T cell receptors (αβ-TCR) or γδ T cell receptors. γδ T cells are supposed to recognize 
heat-shock proteins and unorthodox nucleotides and phospholipids bound to non-
classical MHC molecules such as CD1 and, additionally, might have regulatory 
effects. αβ T cells recognize processed antigen presented on major histocompatibility 
complex (MHC) molecules on the surface of cells. T cells expressing the αβ-TCR are 
CD8+ T cells, CD4+ T cells or NK T cells. Double positive (CD4+ CD8+) T cells pass 
through the thymus during development where they undergo a positive selection by 
self MHC molecules. Binding to a MHC class I molecule results in loss of CD4 
expression, therefore the T cell becomes CD8 positive. If the T cell binds to MHC 
class II molecules it becomes CD4 positive. T cells binding to neither self MHC class 
I nor class II molecules die. Negative selection removes T cells expressing a TCR 
which recognizes self-peptides to prevent self-destruction. Nevertheless, some 
antigens presented in tissues or organs are not present in the thymus. Self-reactive T 
cells recognizing peptides from those antigens become anergic in the periphery. This 
is due to a lack of additional signals needed during the first antigen contact. Thus, T 
cells can distinguish between self and non-self or malignant antigens.  
T cells that survived as well positive as negative selection in the thymus are named 
naive T cells which circle through the body via the blood and lymph streams. Contact 
between a professional APC providing a suitable MHC/peptide complex and a co-
stimulatory second signal leads to the activation of the T cell, a process called 
priming. Activated T cells proliferate and differentiate into armed effector T cells, 
either cytotoxic T lymphocytes (CTLs), in the case of CD8+ T cells, or TH1 and TH2 
cells, in the case of CD4+ T cells. CTLs are able to destroy their target cells via the 
induction of apoptosis, either using perforin and granzymes [17] or Fas-ligand 
interaction [18; 19]. TH1 cells secrete IFNγ and interleukin 2 (IL-2) [20] leading to 
activation of macrophages and CD8+ T cells. In turn, TH2 cells support a humoral 
immune response by secretion of IL-4 [21] what leads to an activation of antibody 
secreting B cells and the complement system.  
Another T cell population was described which are CD4+ and express constitutively 
CD25 [22]. These cells were named regulatory T cells (Treg). They are able to inhibit 
T cell reactions, a process which is not completely understood until now. 
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1.4 The Human Cytomegalovirus 
 
The human cytomegalovirus (HCMV) is a ß-herpesvirus which is characterized by its 
strict host specificity. It provokes an acute infection followed by a lifelong persistence 
of the virus in the human organism with episodes of endogenous reactivation [23]. 
HCMV infects the host via mucosal contacts or parenterally via infected cells in the 
blood. Furthermore, there is intrauterine (congenital infection), perinatal (cervix 
secretions) and postnatal (breast milk) virus transmission, [24-27] which occurs also 
by saliva and sexual contact [28].  
HCMV infection is common worldwide. The prevalence increases continuously after 
the childhood. In developed countries 10% - 20% of all children and 40% - 100% of 
adults are HCMV-seropositive [29] whereas the status in developing countries is 
much higher [29].  
Generally HCMV causes only minor symptoms in immunocompetent individuals, [30] 
mostly in terms of mononucleosis [24]. After this initial response, healthy individuals 
carry the virus as a latent infection. Evidences for a major role of T cells in the 
immune control of this persistent infection are provided by the uncontrolled viral 
replication and HCMV end-organ diseases observed in immunocompromised 
individuals with severely impaired T cell functions like transplant recipients or AIDS-
patients [31; 32]. Thus, the virus appears to be a major cause of morbidity and 
mortality in immunocompromised persons. In these patients the most frequent 
manifestation of severe uncontrolled HCMV reactivation is retinitis [33-36], hepatitis 
[37; 38] and pneumonia [39; 40] as well as gastro-intestinal erosions and ulcer [41-
43].  
Furthermore, severe aetiopathology are described in children infected intrauterine 
[23; 44; 45]. Congenital infection is associated with a range of clinical manifestation, 
but relatively few infected infants are severely ill at birth. In many, the signs and 
symptoms may be subtle or non-specific during the newborn period and during early 
childhood, even as the child experiences progressive hearing damage and as serious 
consequences of infection, including mental retardation, cerebral palsy, and impaired 
vision, become apparent [46]. HCMV is one of the most important causes, infectious 
or non-infectious, of deafness in children [44]. 
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1.4.1 The control of HCMV by the immune system 
 
Both innate and adaptive arms of the immune response are of importance for the 
control of HCMV infection. Within the adaptive immune response, both T cells and 
antibodies have been shown to protect from acquisition of HCMV or from serious 
disease in different settings [47-49]. Some studies suggest that transplacentally 
acquired or passively administered antibody protects against HCMV disease in 
neonates and transplant recipients. Antibodies, presumably capable of neutralizing 
infectivity, can have a role in protection against infection or disease [30; 50]. 
Nevertheless, antibodies are not typically sufficient to control HCMV infection. Virus-
specific T cell immunity is the most important adaptive immune component.  
HCMV can not be eliminated by the host immune response, although the titer of the 
virus in the mucosa and the peripheral blood is reduced and the virus becomes 
undetectable – persistence and latency are established. Once infection has occurred, 
the role of the immune system is to suppress replication and to establish and 
maintain the balance such, that reactivations of the virus remain subclinical. The 
characterization of the immune response against HCMV turn out to be quite difficult 
because most HCMV infections are asymptomatic making it impossible to examine 
the early phases of host response to the virus [28]. However, experiments in 
immunocompromised bone marrow transplant recipients [51-54] demonstrate that 
CMV-specific cell-mediated immunity is essential to control the disease. The innate 
immune response may augment the adaptive immune response, and the magnitude 
of the initial adaptive immune response is important in determining the numbers of 
antigen-specific memory T cells.  
Natural killer cells (NK cells) may also be mentioned to play an important role in the 
passage from innate immune response to adaptive immunity against HCMV infection. 
The production of IFNγ by NK cells facilitates the expansion of antigen-specific TH 
cells which are critical for HCMV control [32; 55]. During initial infection, the 
frequence of HCMV-specific CD8+ T cells raises to a very high level. After 
suppression of viral replication many of HCMV-specific T cells die, but compared to 
other common viral pathogens, the numbers of circulating T cells that recognize 
HCMV peptides remain quite high [56; 57]. HCMV-specific HLA class I-restricted T 
cell responses are known to be essential for successful resolution of the infection and 
maintenance of long-term control of HCMV replication [58-61]. Two HCMV proteins 
Introduction 10
serve as key target antigens for HCMV-specific T cells: a late matrix protein (pp65; 
UL83) that is abundant throughout HCMV infection and an immediate early 1 (IE1; 
UL123) antigen protein that is indispensable for viral replication [62]. For a certain 
time IE1 was not considered a relevant target because reports had suggested that it 
was not efficiently presented on MHC class I after infection [63]. By contrast, virion 
proteins were known to be presented even in the absence of viral replication [64], 
and additionally, pp65 itself was found to interfere with IE1 presentation [65]. 
Therefore, research focussed on pp65 for several years [66; 67]. In 1999, IE1 
became again of interest as a T cell target after IE1-specific CD8+ T cells were 
detected in infected individuals at frequencies at least comparable to those of CD8+ T 
cells specific for pp65 [68]. To date, both pp65 and IE1 are considered dominant T 
cell targets [69; 70]. All in all, many of the antigen-specific CD8+ T cells recognize 
peptides of the pp65 or IE1 protein, although the spectrum of antigen recognition 
may include other viral proteins [71; 72]. HCMV glycoprotein B and other viral 
glycoproteins are targets of IgG, IgM, and IgA antibodies and are also recognized by 
T cells [73]. 
 
1.4.2 Vaccine development against HCMV 
 
Vaccines against infectious agents are one hallmark of immunology and are of high 
success in diseases such as polio, measles, hepatitis B and tetanus [74]. 
Nevertheless, many infectious agents still evade the immune system and lead to 
severe infections. HCMV causes a spectrum of disease syndromes in children and 
adults. HCMV is a cause of mononucleosis in immunocompetent individuals and is a 
well-known cause of serious morbidity and sometimes fatal infections in 
immunocompromised patients especially recipients of solid-organ or hematopoetic 
cell allografts and individuals with advanced AIDS [75; 76]. Antiviral drugs have 
constituted an important advance for prevention or resolution of HCMV infections 
especially with regard to early posttransplant time. Nevertheless, long-term control of 
the persistent virus in the host will depend on the ability to raise an adequate immune 
response to the perspective pathogen. Studies in animal models of experimental 
infection and human studies have shown that the induction and perpetuation of virus-
specific CD8+ and CD4+ T cells is sufficient and often essential for the resolution of 
infection [77; 78]. Moreover, CD8+ and CD4+ αβ-T cells provide an immunologic 
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memory response which may have major significance with regard to protective 
immunity to cytomegalovirus infection [79]. First studies which suggested a critical 
role of αβ-T cells in HCMV infection used a model with murine cytomegalovirus 
(MCMV). MCMV is genetically distinct from HCMV, but the pathogenesis of infection 
in immunosuppressed mice is similar to that for human CMV [80; 81]. In humans 
several studies examined the relationship between quantitative deficiency of virus-
specific αβ T cell responses and progressive human HCMV infection in allogeneic 
hematopoetic cell transplant and solid organ transplant recipients [32].  
Several technologies were developed for determining antigen-specific T cells, e.g. 
intracellular cytokine staining or staining with tetrameric MHC class I/peptide 
complexes. These have further confirmed the role of HCMV-specific T cells in 
controlling HCMV infection – in healthy HCMV-seropositive individuals, up to 40% of 
all T cells in the peripheral blood can be specific for HCMV [82] emphasizing the 
importance of a strong HCMV-specific cellular immunity in persistent HCMV infection. 
Furthermore, strategies to isolate and expand clonal populations of αβ-T cells with 
defined specificity for viral antigens became well-established and benefits adoptive 
cellular immunotherapy. For adoptive cellular immunotherapy, CD8+ HCMV-specific T 
cell clones were cultured in vitro by cyclic stimulations of the T cells in presence of 
donor-derived γ-irradiated feeder cells and Interleukin-2 (IL-2) to promote numeric 
expansion. Clones that were αβ-TCR+, CD3+, CD8+, and CD4-, and recognized 
epitopes derived from structural virion proteins and presented by MHC class I were 
selected for intravenous administration to the recipient [83]. This first study on 
adoptive transfer of CD8+ HCMV-specific T cell clones in allogeneic hematopoetic 
cell transplant recipients has proved safety and effectiveness of the method to 
restore CD8+ HCMV-specific cytotoxic T cell immunity.  
Further studies for the treatment of HMCV infection make use of dendritic cells which 
are pulsed with peptide or protein, or HCMV-specific CD4+ T cells what was shown to 
be effective in inducing HCMV-specific CD8+ T cell responses and reduction in 
HCMV viral DNA load [84]. New perceptions made in the field of the generation of 
antigen-specific T cells offered better conditions for adoptive immunotherapy. These 
include use of monocytes, dendritic cells, B lymphoblastoid cell lines as presenting 
cells of antigen delivered by pulsing with exogenous peptides or proteins [85], or of 
antigen processed endogenously after transduction with viral vectors. Moreover, 
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genetically modified T cells are used for adoptive immunotherapy offering the 
potential to be safe and efficient [86; 87].  
As described above, protective responses to infectious agents like HCMV rely largely 
on T cells. Therefore, not only adoptive transfer of T cells is an approach for antiviral 
immunotherapy. Also the use of a peptide-based vaccine may be in focus of 
discussion. A main part of this thesis has the major objective to identify and 
characterize T cell responses specific for epitopes of HMCV which can be used to 
design a synthetic HCMV vaccine. 
 
1.5 Immunotherapy in cancer 
 
1.5.1 Clinical trials 
 
Currently available therapeutic measures like radiotherapy and chemotherapy often 
suffer from severe toxicity and lack of specificity of the therapy towards tumor cells. In 
the last decades understanding of the immune response to cancer have led to new 
opportunities for the development of effective immunotherapies against cancer. 
Several clinical trials demonstrated that the immune system can be manipulated to 
specifically recognize and eliminate tumor cells [88; 89]. There are numerous 
strategies to activate an immune reaction against growing cancer whereby dendritic 
cells (DCs) play an important role, e.g. transfection of dendritic cells with total RNA 
[90] or RNA coding for defined tumor antigens [91], or DCs loaded with proteins [92; 
93] or MHC class I peptides from tumor associated antigens [94]. Simply peptides in 
association with adjuvants such as GM-CSF or keyhole-limpet hemocyanin (KLH) 
[95], Interleukin 2 [96], Montanide ISA-51 [97], tumor associated [98] or artificial MHC 
class II ligands [99] can also be used to enhance a T cell response. Furthermore, 
there are approaches using hybrid cells designed by fusion of tumor cells and 
professional antigen presenting cells [100; 101], irradiated allogenic [102] or 
autologous tumor cells [103] which are manipulated to become more immunogenetic, 
recombinant virus used as transporters for DNA coding for tumor rejection [104] or 
autologous tumor-derived heat shock proteins [105].  
By the expression of tumor antigens tumor cells may stand out from their 
surrounding. Many tumor antigens were identified which are either tumor specific 
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meaning they only appear in tumor tissue, for example cancer-testis antigens, 
mutated antigens and tumor-virus antigens, or tumor associated antigens which are 
highly overexpressed in tumors but can also be found in normal tissue, as for 
example differentiation antigens. Table 1 shows a classification of tumor rejection 
antigens. 
 
 
Table 1: Classes of tumor antigens* 
class examples recognized by 
T cells   antibodies
Point mutation of normal gene CDK4 [106] + -
frame shift mutation of normal gene TGFβRII [107] + -
anti sense transcript of normal gene RU2AS [108] + -
expressed intron of normal gene N-acetylglucosaminyltransferase V 
[109] 
+ -
fusion protein caused by translocation BCR-ABL [110] + -
fusion protein caused by posttrans. mod. gp100 [111] + -
altered posttranslational modification Tyrosinase [112] + -
cancer/embryonic antigen CEA [113; 114] + +
overexpressed antigens – protein Her2/neu, MUC1 [115; 116] + +
overexpressed antigens – non-protein ganglioside GD3 [117] - +
cancer testis antigen NY-ESO-1 [118] 
MAGE family [119] 
 
+ +
oncogenes Ras [120-122] + +
tumor suppressor genes p53 [123; 124] + +
differentiation antigen Tyrosinase [125; 126] 
gp100 [127; 128] 
+ 
+ 
+
+
viral proteins HPV E7 [129; 130] + +
* adapted from Rammensee et al. [131] 
 
Vaccines against cancer aim to induce tumor-specific effector T cells that are able to 
reduce the mass of the tumor, as well as tumor-specific memory T cells that can 
control tumor relapse.  
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1.5.2 Lymphocytes and tumor regression 
 
Identification of defined tumor antigens in humans [132; 133] facilitates the 
development of adoptive T cell therapy. An innovative strategy for vaccination should 
combine as well induction of therapeutic T cell immunity in form of tumor-specific 
effector T cells as protective T cell immunity in form of tumor-specific memory T cells 
which can control tumor relapse [134-136]. Several studies have been shown that 
cytotoxic T cells are able to recognize tumor rejection antigens on tumor cells and 
therefore may contribute to tumor regression [137; 138]. CD4+ helper T cells also 
play an important role in orchestrating the effector function of anti-tumor T cell 
responses [139] therefore the identification of CD4+ T cell epitopes derived from 
tumor-associated antigens has recently been a major focus of attention [140; 141]. All 
in all, to elicit a long lasting anti-tumor immune response the effector CTL response 
should be accompanied by effector CD4+ T cells [136; 139]. Moreover, studies have 
shown that CD4+ T cells are able to induce an anti-tumor immune response without 
any CTL effector function mostly causes by indirect effects of IFNγ [142-145] or by 
induction of antibody production and therefore tumor immunity [146]. 
 
1.6 Analysis of antigen specific T cell responses 
 
As mentioned above monitoring of the immune response occurring during 
autoimmunity, infection, transplantation or after vaccination is of major interest for 
immunologists. The normally low frequency of T cells specific for an antigen is a 
steady problem for the analysis of antigen specific T cell responses. The frequency of 
naive peripheral T cells against a given antigen has been estimated between 4x10-8 
and 2x10-5 [147-149] but may increase during T cell responses up to 6x10-1 among 
CD8+ T cells [150]. Furthermore, one has to think about different functionalities and 
pathways of activation between naive, effector, and memory T cells. Assays to 
measure T cell responses are characterized by several features: assay accuracy and 
precision, limit of detection, limit of quantitation, specificity, linearity and range, 
ruggedness, robustness, and system suitability. Accuracy refers to the correctness 
and exactness of the test result. It is defined as the closeness of a test result to the 
true value and can only be calculated by comparison with a standard. But definition 
of standards for T cell assays is difficult. Nevertheless, the use of commonly occuring 
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antigens and the generation of T cell clones specific for positive control antigens such 
as cytomegalovirus and influenza may provide standards for determining the 
accuracy of T cell methodologies to be evaluated. Precision or reproducibility of an 
assay is defined as the closeness of a test results to another when using the same 
specimen. This parameter is expressed as a standard deviation and variation 
coefficient of multiple samples making known positive controls indispensable. The 
detection limit of a method is the capacity to detect small amounts of a substance 
with a certain reliability and can be assessed by spiking a negative sample with 
known quantities of well-characterized T cells, e.g., CMV clones in a CMV negative 
HLA matched donor. The detection limit of a method is distinct from its sensitivity, 
which is the proportion of true positives among positive values (e.g. high sensitivity 
equates to a low amount of false negatives). Sensitivity of an assay is the parameter 
most affected by background noise. Specificity reflects the ability to measure true 
negatives as negative (e.g. high specificity equates to a low amount of false 
positives). 
A reliable method to measure T cell responses should be able to maintain accuracy, 
precision, sensitivity, and specificity despite changes in external factors such as 
technicians, instruments, or reagents.  
 
1.6.1 Functional T cell assays 
 
T cells respond with measurable effects after they got in contact with antigen 
presented on MHC complexes which are expressed by target cells. These effects can 
be cytokine expression, expression of activation markers, proliferation, degranulation, 
target cell cytotoxicitiy and/or trogocytosis. 
Several methods exist for the detection of cytokines expressed by antigen specific T 
cells. All these assays can be performed specifically for different cytokines, 
depending on the expected functionality of the cells. Thereby, interferon γ (IFNγ) is 
one of the most important cytokine for the detection of activated CD8+ or CD4+ T 
cells.  
Bulk cytokine expression assays on a protein level are classic sandwich enzyme 
linked immunosorbent assays (ELISAs) [151] or similar protein detection assays such 
as the cytometric bead assay [152]. These methods allow simultaneous detection of 
several cytokines within one sample. On mRNA level, quantitative reverse 
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transcription polymerase chain reaction (qRT-PCR) has been exploited. This assay is 
based on the principle that amplification of cDNA by polymerase chain reaction 
follows a strict mathematical equation whereby with each cycle of amplification two 
copies are made from each individual oligonucleotide species [153]. 
Three methods exist to enumerate single cytokine-secreting T cells in response to 
specific (peptide) antigens: enzyme linked immunospot (ELISpot) assay [154; 155], 
intracellular cytokine staining [156] and cytokine capture [157].  
The ELISpot assay is based on the principle of the ELISA. A Nitrocellulose-bottomed 
microtiter plate is coated with an antibody that binds the cytokine of interest. Antigen-
specific T cells, either unseparated PBMCs or CD8+ or CD4+ T cells are incubated in 
the plate together with the antigen to test. Recognition of the antigen leads to release 
of cytokine of interest, which is then bound by the antibody coated on the plate. 
Cytokine release is visualized by an enzyme-labeled detection-antibody and a 
corresponding chromogenic substrate which has to be non-soluble to precipitate at 
the bottom of the well. Cytokine secreting T cells become visible as colored spots. 
The ELISpot assay requires a short-term stimulation with synthetic peptide. 
Therefore, T cells are stimulated in vitro. Nevertheless, the assay detects only T cells 
that are preactivated in vivo, since naive T cells do not secrete cytokines upon short-
term stimulation. Thus, the ELISpot assay is useful to measure number and 
functionality of antigen-specific T cells ex vivo. Results can be expressed in terms of 
relative frequencies of antigen-specific T cells what enables a direct comparison of 
the strength of in vivo T cell responses between groups of patients and between 
different clinical trials [158-160]. 
Intracellular cytokine staining is based on direct detection of intracellular cytokine 
expression with fluorochrome-conjugated anti-cytokine antibodies after short periods 
of activation with antigens. The assay can be performed with PBMCs [161], whole 
blood [162; 163], lymph nodes, or other biologic fluids. Intracellular cytokine detection 
raises the problem that cytokines are usually rapidly secreted and diffuse away from 
the secreting cell. Therefore, a total incubation period of 6 hours is optimal for 
achieving high levels of cytokine-secreting cells for IL-2, IL-4, IFNγ, and TNFα, as 
well as for achieving maximal cytokine staining intensity [162]. Cytokine secretion is 
disrupted usually during the final 4 hours of incubation by the addition of drugs 
inhibiting cytokine secretion such as monensin or brefeldin A [164]. After staining with 
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surface markers like anti-CD8 or anti-CD4, cell membranes are permeabilized using 
non-ionic detergents, followed by intracellular staining of cytokine of interest.  
In cytokine capture assays, cells are labeled with a capture matrix like anti-cytokine 
antibodies which are non-covalently coupled to the cell surface. After stimulation, 
secreted cytokines are captured on the cell surface and can be later stained with a 
fluorescently labeled second anti-cytokine antibody. Because this method does not 
affect viability it is very useful if a live cell sorting is performed.  
Activated T cells express proteins which are not found on resting T cells. Common 
activation markers are: CD69, CD25 and HLA-DR (in human T cells). Single-cell 
assays have been employed that use flow cytometric staining of the surface markers 
on activated T cells [165]. Disadvantages of this method are narrow, distinct time 
windows in which the molecules are expressed and the fact that these surface 
markers are also found on subpopulations of ex vivo isolated T cells in the absence 
of antigen [166].  
A very important in vitro parameter for in vivo function is T cell proliferation. The 
proliferation of T cells in response to in vitro stimulation is commonly determined by a 
radioactive method which is based on incorporation of [3H]thymidine into newly 
generated DNA [167]. This method is widely applied but has some disadvantages. 
First, the method requires radioactive facilities. Additionally, this technology gives 
only information on the overall proliferative responses, but does not give any 
information about the specific cell subsets involved in these responses.  
Alternative methods to measure T cell proliferation are the assessment of CD38 
expression on T cells analyzed by flow cytometry and an enzyme-linked 
immunosorbent assay (ELISA) based on 5-bromo-2´deoxyuridine (BrdU) 
incorporation into newly synthesized DNA of proliferating T cells [168]. Furthermore, 
it is possible to prelabel cells with fluorescent dye 5,6-carboxylfluorescein diacetate 
succinimidyl ester (CFSE) [169]. Proliferation, in response to antigen recognition, 
results in reduction of CFSE intensity what can be measured directly by flow 
cytometry.  
Antigen-specific cytotoxic T cells (CTLs) can be detected by degranulation. Activation 
of CTLs leads to the fusion of cytotoxic granula with the cell membrane followed by 
release in the extracellular environment. Proteins like CD107a/b which are normally 
found on the membrane of the granula, become transiently located to the cell 
membrane. This effect is strongly associated to cytotoxicity and can be used to 
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detect and sort antigen-specific CD8+ T cells [170] by a single-cell based assay that 
employs staining cells during and after activation with fluorescent anti-CD107a/b 
antibodies and flow cytometry.  
Another effect of functionality of activated CD8+ T cells is the ability to lyse target 
cells. The first described method for the detection of CTLs is the 51Chromium-release 
assay (CRA) [171; 172] which can be performed either on fresh cells [Plata, 1987; 
Walker, 1987; Riviere, 1989] by measuring effector CTL activity, or on CTL lines 
[Walker, 1987; Nixon, 1988] by evaluating memory CTL activity. Target cells are 
labeled with 51Cr(VI)O42-, a radiochemical compound which is able to enter cells 
through anion transport systems. In the cytoplasm it is subsequently reduced to 
51Cr(III). As Cr(III) will reside inside the cell, cellular accumulation of 51Cr is greatly 
facilitated [173]. Labeled target cells are incubated with effector cells (CD8+ T cells) 
for several hours. If the effector cells recognize antigen presenting target cells they 
will lyse them, 51Cr will be released from the cell and becomes detectable in the 
supernatant. This assay is very useful for the determination of direct cytotoxicity of T 
cells but is inadequate for ex vivo studies that require the quantification of antigen-
specific CD8+ T cells in a mixed lymphoid population. A standard CRA does not 
determine CTL frequencies except if used in a limiting dilution analysis.  
Recently, Snyder et al. described a new-single cell based assay to measure the 
frequency of antigen-specific functional CTLs [174] – the “Lysispot”. In this assay, 
target cells are transfected with a beta-galactosidase vector and coincubated with 
effector cells on top of flat membrane, which is non-covalently linked to an anti-
galactosidase antibody. Release of beta-galactosidase after lysis is fixed as a spot on 
the membrane that can be visualized by the inherent enzymatic activity of beta-
galactosidase or by means of an enzyme-linked second anti-galactosidase antibody 
in correlation with a substrate.  
During trogocytosis performed by all lymphocytes, surface material from the antigen 
presenting cell to the effector cell is transferred but the mechanism and biological 
function of this effect are unknown until now [175]. However, it is an effect which can 
be used for the detection of antigen presenting CD8+ T cells [175; 176]. For this 
purpose, target cells are labeled by coupling green fluorescent protein (GFP) to HLA 
molecule expressed by the target cell, loaded with antigen and incubated with 
antigen-specific T cells. These aquire HLA-GFP from the target cell and become 
fluorescent and thus detectable by flow cytometry. 
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1.6.2 Assays to determine specificity of T lymphocytes 
 
For a quantification of antigen-specific T lymphocytes with regard to their specificity 
the analysis via fluorescent multimeric MHC-peptide reagents (also called tetramers) 
[177] is useful. These are capable of identifying and enumerating antigen-specific T 
cells and also provide functional information when combined with other 
methodologies. Tetramers are prepared by in vitro folding MHC heavy chain in the 
presence of β2-microglobulin and a specific peptide ligand. Briefly, recombinant MHC 
class I heavy chain that incorporate a short C-terminal substrate peptide for BirA-
mediated biotinylation are produced in Escherichia coli, purified from inclusion 
bodies, folded in the context of synthetic peptides and β2-microglobulin and 
biotinylated. Based on the specific application, fluochrome-labeled streptavidin, an 
avidin-like protein from Streptomyces avidinii which has four binding sites for biotin 
with high affinity [178], is added to purified MHC/peptide monomers to form soluble 
tetrameric complexes (Figure 3). MHC/peptide tetramers will bind T cells bearing 
MHC/peptide-specific T cell receptors and can be detected by flow cytometry (Figure 
3). Moreover, phenotypic characterisation of cells detected by tetramer staining is 
enabled by possible parallel detection of co-expressed cell surface antigens [179]. 
MHC class II-peptide tetramers have also been developed for the assessment of 
CD4+ T cell responses [180-182].  
But even if these multimeric MHC/peptide reagents offered new possibilities to 
analyse whole T cell responses against a given epitope, there are also some 
limitations. First, MHC/peptide tetramers stably bind to TCR exhibiting a certain 
minimal avidity. Hence, functional T cells may be missed in this assay depending on 
the staining conditions, e.g. temperature [183-185] or concentration of tetramers. 
Moreover, MHC/peptide tetramers also interact with the CD8/CD4 coreceptor and 
may therefore influence binding of anti-CD8 antibodies [186; 187] what may lead to 
peptide independent binding and ultimately false positive results. Secondly, 
MHC/peptide tetramers are also known to bind other receptors such as killer cell 
immunoglobulin-like receptors (KIRs) or immunoglobulin-like transcripts (ILTs) 
expressed on natural killer cells [188-190]. 
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Figure 3. (a) Soluble heavy chain of MHC class I molecules are synthesised in Escherichia coli. (b) 
The molecules adopt an appropriate conformation following the addition of β2 microglobulin (β2m) and 
a synthetic peptide. Enzyme BirA is used to attach a biotin molecule. (c) Four MHC–biotin complexes 
are linked to a single streptavidin molecule labeled with a fluorochrome to form a tetramer. (d) 
Tetramers are mixed with the T cell population. Only T cells that have TCRs capable of binding to the 
particular MHC–peptide combination present in the tetramer are able to bind the tetramer. Such cells 
become labelled with the fluorochrome [shown in red on the graph in (e)]. A monoclonal antibody 
specific for a T cell marker and tagged with a different fluorochrome (shown in green) can be used. (e) 
Cells are analyzed by flow cytometry. 
 
1.7 In vitro stimulation of antigen-specific T cells 
 
The use of antigen specific T cells in adoptive immunotherapy is correlated with 
injection of large amounts of previously amplified antigen specific T cells. Therefore, 
it is important to separate T cells specific for an antigen of desire out of a whole T cell 
population. It is possible to stimulate and amplify T cells either in an antigen 
www-ermm.cbcu.cam.ac.uk/ jhc/fig004jhc.htm 
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independent manner or by stimulation with specific antigen. In mixed T cell 
populations, composition may change after antigen independent stimulation because 
not all subpopulations will divide and survive in the same way. However, mixed T cell 
populations can be separated using fluorescence activated- or magnetic affinity cell 
sorting (FACS/MACS) systems [191-194] or populations can be cloned by limiting 
dilution [195]. Antigen independent amplification of T cells can be achieved using 
polyclonal mitogens or stimulatory antibodies, usually in combination with cytokines 
like IL-2 [196]. Several antibodies able to support T cell stimulation are known, e.g. 
antiCD3 [196] or antibodies directed against costimulatory antigens such as CD28 
[197], 4-1BB [198] or CD27 [199; 200], respectively. Polyclonal mitogens can be 
concanavalin A (Con A) [201] or phytohaemagglutinin (PHA) [202].  
For stimulation and proliferation of antigen-specific T cells in vitro several approaches 
can be used. Memory T cells can be stimulated with peptides [203] or proteins loaded 
on non-professional antigen presenting cells within autologous primary cells, 
autologous derived B-lymphoblastoid cell lines or allogeneic cell lines. Expansion of 
naive T cells, called in vitro priming, can be achieved using autologous monocyte 
derived dendritic cells [204] or autologous activated B lymphocytes [205] loaded with 
antigens, e.g. peptides [206]. Nevertheless, generation of these professional antigen 
presenting cells is expensive, time-consuming and only low numbers can isolated 
and generated. Therefore, different approaches were developed using artificial 
antigen presenting cells (aAPCs). Allogeneic tumor cells, e.g. K562, can be 
transfected with costimulatory and adhesion molecules, such as CD80, 4-1BBL, LFA-
3 and ICAM-1 [207]. Possible effects of allostimulation are avoided by transfection of 
single peptide-HLA complexes into HLA-deficient cells [208].  
In another approach to design aAPCs, recombinant MHC/peptide complexes 
(monomers) are coated on plastic microspheres [209; 210], lipid vesicles [211] or 
HLA deficient cell surfaces [194].  
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1.8 Aims of thesis 
 
HCMV is a cause of severe diseases in immunocompromised individuals such as 
transplant recipients or AIDS patients, therefore, it is very important to search for new 
opportunities in vaccine development. As HCMV is controlled by CD8+ and CD4+ T 
cell responses in immunocompetent persons, detailed knowledge of T cell responses 
against HCMV is essential for the development of a HCMV vaccine. One aim of this 
thesis was the investigation of natural frequencies of CD8+ and CD4+ T cells in 
healthy donors. A further field of interest was the characterization of 
immunodominant features or any hierachies between the epitopes identified. As 
peptide-based immunotherapy is restricted by many different HLA-types of patients it 
was also important to identify T cell epitopes with distinct HLA restrictions. 
Several clinical trials could show that the immune system can be manipulated to 
specifically recognize and eliminate tumor cells [212; 213]. Peptide based 
immunotherapy is capable to raise cytotoxic T cells which are able to recognize 
tumor rejection antigens on tumor cells and are thus able to contribute to tumor 
regression. Therefore, it is very important to enlarge knowledge of anti-tumor T cells 
and their epitopes. Thus, another aim of this thesis was the induction and analysis of 
CD4+ and CD8+ T cells specific for peptides from tumor-associated antigens.  
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2 Results and Discussion, Part 1: T cell epitopes of HCMV 
 
 
2.1 Major contribution of codominant CD8 and CD4 T cell 
epitopes to the Human Cytomegalovirus-specific T cell 
repertoire 
 
This manuscript has been composed by Maria-Dorothea Nastke*, Leah Herrgen*, 
Steffen Walter, Dorothee Wernet, Hans-Georg Rammensee and Stefan Stevanović. 
The author of this thesis has performed the experiments leading to Figures 1, 2, 3, 
and 4 and Table 1, 2, 3. Parts of this chapter are published in Cellular and Molecular 
Life Science 62, 77-86 (2005). 
* These two authors contributed equally to this work. 
 
Summary 
 
Human cytomegalovirus (HCMV) infection or reactivation is a cause of morbidity and 
mortality in immunocompromised individuals. In immunocompetent individuals, in 
contrast, HCMV is successfully controlled by specific CD8 and CD4 T cells. 
Knowledge of CD8 and CD4 T cell epitopes from HCMV and their immunodominant 
features is crucial for the generation of epitope-specific T cells for adoptive 
immunotherapy and for the development of a peptide-based HCMV vaccine. 
Therefore, we investigated the natural frequencies of a large number of CD8 and 
CD4 T cell epitopes, including 10 novel ones. We determined several epitopes as 
immunodominant. Surprisingly, no clear hierarchies were found for CD8 T cell 
epitopes, indicating codominance. These results will be valuable for adoptive transfer 
strategies and support initiatives towards development of a peptide-based HCMV 
vaccine. 
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Introduction 
 
Human cytomegalovirus (HCMV) infection is normally asymptomatic in 
immunocompetent individuals [1]. However, primary HCMV infection [1; 2] or 
reactivation of HCMV from latency [3] are causes of significant morbidity and 
mortality in immunocompromised individuals such as transplant recipients. In non-
immunocompromised seropositive individuals, HCMV-specific cytotoxic T 
lymphocytes (CTLs) are present in high frequencies in the peripheral blood [4], and 
there is a direct correlation between the recovery of HCMV-specific CTL responses 
with an improved outcome of HCMV disease [5]. The concept of adoptive 
immunotherapy was derived [6], and the adoptive transfer of HCMV-specific CTL 
clones [7; 8] or HCMV-specific T cell lines [9] has successfully protected patients at 
risk from HCMV disease. The importance of T helper cells (TH) in primary HCMV 
infection [10] as well as for expansion of memory CD8 T cells [11] has lately been 
emphasized. Furthermore, several studies have outlined the significance of antiviral 
effector functions of TH cells in maintaining CTL responses after adoptive transfer 
[12; 13] and their capacity to produce antiviral cytokines [10; 14]. These findings 
underline the importance of T cell immunity in the control of HCMV infection and the 
relevance of T-cell-based approaches in therapeutic settings. 
Knowledge of HCMV epitopes is crucial not only for monitoring of antiviral immunity 
but also for the in vitro generation of antiviral CTLs for possible application in 
adoptive immunotherapy. Several studies have already been successful in the 
identification of HCMV epitopes [14-29]. According to Sercarz et al. [30], 
immunodominant epitopes are defined as those that account for the bulk of the global 
specific T cell response within one individual. However, we use this term to refer to 
the frequency of responders among individuals carrying the restricting allele, while 
we refer to codominance as the responsiveness of a single donor against more than 
one epitope derived from a given protein. Identification of a sufficiently large number 
of CTL and TH epitopes as well as knowledge of immunodominance of individual 
epitopes and epitope hierarchies on individual MHC alleles is pivotal for development 
of an HCMV vaccine. In addition, the use of well-defined peptides for the generation 
of HCMV-specific T cells for adoptive immunotherapy is preferential to the use of ill-
defined viral lysates, which have so far mostly been employed for this purpose [9; 
31]. We performed large-scale screenings of HCMV-seropositive donors for 
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determination of immunodominance of known CTL and TH epitopes and for 
identification of novel CTL and TH epitopes. Our experiments focused on pp65 as the 
major target of human CTL reactions, but we also included other HCMV antigens with 
reported CTL responses. In the course of this study, we were able to determine the 
immunodominant features of a great number of CTL and TH epitopes. Furthermore, 
we identified six novel CTL and four novel TH epitopes. 
 
Material and Methods 
 
Donors 
Buffy coats were obtained from healthy blood bank donors of known major 
histocompatibility complex (MHC) class I and II types and of known HCMV 
serostatus. The local Ethics Committee approved this study. Peripheral blood 
mononuclear cells (PBMCs) were isolated from fresh buffy coats using standard 
gradient separation (Lymphocyte Separation Medium, PAA Laboratories, Pasching, 
Austria) and cryopreserved in fetal calf serum (FCS) (PAA Laboratories, Pasching, 
Austria) with 10% DMSO (Merck, Darmstadt, Germany) at –80°C until further use.  
 
Peptides, recombinant MHC molecules and fluorescent tetramers 
Peptides from HCMV pp65, pp50 and IE1 were synthesized by standard Fmoc 
chemistry using a Synergy Personal Peptide Synthesizer 432A (Applied Biosystems, 
Weiterstadt, Germany) or alternatively using the Econ- omy Peptide Synthesizer EPS 
221 (ABIMED, Langen, Germany). HLA class I restricted peptides were either 
selected according to epitope prediction using the SYFPEITHI database [32] or 
according to published CTL epitope sequences. A panel of 15–20mer peptides 
constituting potential HLA-DR epitopes from pp65 and IE-1 for CD4 T-cell-epitope 
screening was selected according to several HLA-DR peptide motifs [32], 
http://www.syfpeithi.de ]. Peptide pools for CD4 T-cellepitope screening consisted of 
three to five peptides with single peptide concentrations of 5 μg/ml. Peptides were 
dissolved at 10 mg/ml in DMSO (Merck), diluted 1:10 in ddH2O and aliquots stored at 
–80°C. Biotinylated recombinant MHC class I molecules and fluorescent MHC 
tetramers for immunodominance studies and verification of predicted CD8 T cell 
epitopes were produced as described earlier [33]. Briefly, fluorescent tetramers were 
generated by coincubating biotinylated HLA monomers with streptavidin-PE or 
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streptavidin- APC (Molecular Probes, Leiden, the Netherlands) at a 4:1 molar ratio. 
For all HLA-B*44 peptides, HLA-B*4405 monomers were used. The used HLA-
B*2705 tetramers had a cysteine-to-serine mutation in position 67. 
 
Reagents and media 
T cell medium consisted of RPMI 1640 containing HEPES and L-glutamin (Gibco, 
Paisley, UK) supplemented with 10% heat-inactivated human serum (PAA, Cölbe, 
Germany), 50 U/ml penicillin, 50 μg/ml streptomycin and 20 μg/ml gentamicin (all 
BioWhittaker, Verviers, Belgium). PBE was PBS ( BioWhittaker, Verviers, Belgium) 
containing 0.5% of bovine serum albumin (Sigma Aldrich) and 2 mM EDTA (Roth, 
Karlsruhe, Germany). PFEA was PBS supplemented with 2% heat inactivated FCS 
(PAN Biotech, Aidenbach, Germany), 2 mM EDTA (Roth) and 0.01% sodium azide 
(Merck, Darmstadt, Germany). TSB (tetramer staining buffer) was PBS 
(BioWhittaker/Cambrex) containing 50% FCS (PAA), 2 mM EDTA (Sigma Aldrich) 
and 0.02% NaN3 (Merck). 
 
Peptide stimulation and intracellular IFNγ staining 
Cryopreserved PBMCs were thawed, washed two times in PBE, resuspended at 107 
cells/ml in T cell medium and cultured overnight to reduce unspecific interferon-γ (IFN 
γ) production [34]. On the next day, PBMCs were stimulated with 5 μg/ml peptide for 
6 h in the presence of Golgi-Stop (Becton Dickinson) for the final 4 h of incubation. 
Intracellular IFNγ staining was performed for the analysis of CD4 T cell responses 
because it allows for combining IFNγ and CD4 staining. Cells were analyzed using a 
Cytofix/Cytoperm Plus kit (Becton Dickinson, Heidelberg, Germany) plus Abs IFNγ -
PE (Becton Dickinson), CD4-fluoroscein isothiocyanate (FITC) (Immunotools, 
Friesoythe, Germany) and/or CD8-PerCP clone SK1 (Becton Dickinson). After 
staining, cells were analysed on a three-color FACSCalibur (Becton Dickinson). 
 
Tetramer staining 
2 x 106 thawed PBMCs were stained with CD8-PerCP clone SK1 antibody (Becton 
Dickinson) and incubated at 4°C for 20 min in the dark, followed by 30 min incubation 
with fluorescent MHC tetramers at 4°C in the dark. After washing, cells were 
resuspended in 1% paraformaldehyde in PFEA. Cells were analysed by flow 
cytometry on a four-color FACSCalibur cytometer (Becton Dickinson). 
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Combined tetramer staining/intracellular IFNγ -staining 
Two different conditions were used to perform this assay provided enough PBMCs 
were available. PBMCs were stained with tetramer before and after stimulation with 
peptide (condition 1), and with tetramer only after stimulation with peptide (condition 
2), as reported previously [35]. Staining procedures were performed as described 
above using IFNγ-FITC (Becton Dickinson), CD8-PerCP clone SK1 (Becton 
Dickinson) and fluorescent MHC tetramer-PE. 
 
Phenotyping of antigen-specific CD8+ T cells 
Thawed and washed PBMCs were stained with CD8- PerCP clone SK1 (Becton, 
Dickinson) plus either CD45RA-FITC (Becton Dickinson) or CD27-FITC, CD28-FITC, 
CD45RO-FITC, CD57-FITC, CD62LFITC, respectively (all Coulter-Immunotech, 
Hamburg, Germany). For staining with CCR7, cells were first labelled with rat 
hybridoma supernatant 3D12 (kindly provided by R. Förster, Anova). After washing, 
cells were incubated with FITC-labelled donkey anti-rat F(ab´)2 fragments (Jackson 
Immunoresearch Laboratories, West Grove, PA), and blocking with heat-inactivated 
mouse serum (CC pro) was performed. After staining with antibodies, cells were 
washed and labelled with tetramers diluted to 2 μg/ml in TSB. Stained cells were 
washed and fixed in PFEA containing 1% formaldehyde (Merck). Cells were analysed 
on a threecolor FACSCalibur (Becton Dickinson). 
 
51Chromium release assay 
Standard 4 h 51Cr release assay was performed using T2 cells and Awells as target 
cells which were used to load with either 100 nM NLVPMVATV-peptide (HCMV 
pp65495-503) or 100 nM ILKEPVHGV-peptide (HIV-1 RT476-484) as negative control, 
respectively. Furthermore, negative controls without peptide were used. Target cells, 
peptides and 100 µCi Na251CrO4 (NEN Amersham Bioscience, Freiburg, Germany) 
were coincubated for 1 hour at 37°C/5% CO2. After target cells were added to 
effector cells in a 96 well plate and incubated for additionally for 4 hours at 37°C. 50 
µl of supernatant was transferred to a lumaplate (PerkinElmer, Rodgau-Jügesheim, 
Germany) and read-out was performed by scintillations counting (1450 Microbeta 
Plus, PerkinElmerTM life science). Specific lysis was calculated by 100 x 
(experimental release - spontaneous release)/(total release - spontaneous release). 
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IFNγ ELISpot assay 
IFNγ ELISpot assays were performed for the analysis of CD8 T cell responses if no 
tetramers of the respective HLA molecule were available. 96-well nitrocellulose plates 
(MHABS4510, Millipore, Bedford, MA) were coated with a mouse anti-human IFNγ 
antibody (5 μg/ml, Becton Dickinson). 106 thawed PBMCs/well were stimulated with 5 
μg/ml peptide for 24 h, and secreted IFNγ was detected using biotinylated anti-IFNγ 
mAb (1 μg/ml), streptavidin-alkaline phosphatase conjugate (all Becton Dickinson) 
and BCIP/NBT (5-bromo-4-chloro-3-indolylphosphate toluidine and nitroblue 
tetrazolium, Sigma Aldrich, Steinheim, Germany). The plate was washed with water 
and dried overnight. IFNγ-producing cells were detected as purple spots on the 
nitrocellulose membrane of each well. Plates were analysed using the Immunospot 
Image Analyzer (series 1) and ImmunoSpot Software Version 3.2e (both Cellular 
Technology, Cleveland, OH). 
 
Results 
 
Immunodominance of CD8+ T-cell epitopes 
PBMCs of 67 healthy HCMV seropositive donors were tested ex vivo with respect to 
the frequency of specific T cells in their peripheral blood. Reactivity of CD8+ T cells to 
peptides was determined by IFNγ-ELISpot, and specificity of T cell receptors by 
tetramer staining. From our experience, frequencies down to 0.01% among CD8+ T 
cells can be clearly distinguished from background by tetramer staining and 0.01–
0.001% by IFNγ-ELISpot, respectively. HLA tetramers of several allotypes were 
prepared containing HCMV peptides derived from pp65, pp50 and IE- 1, respectively, 
to determine the frequency of responders among donors positive for the restricting 
HLA allele. Epitopes were considered immunodominant if more than 75% of 
seropositive donors showed a T cell response with at least six or more donors tested; 
epitopes with values detected below this average were regarded as subdominant. 
Peptides tested are listed together with references in table 1. Here we determined 
five CTL epitopes presented by three different HLA alleles (HLA-A*0101, HLA-A* 
0201 and HLA-B*0702) to be immunodominant. Among 15 HCMV seropositive 
donors expressing HLA-A1, 14 showed CD8 T cells specific for pp65 363–373 and 
8/10 donors had high frequencies of CTLs specific for peptide pp50 245–253 
(examples in fig. 1A). T cells specific for NLVPMVATV (pp65 495–503) were 
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observed in all HLA-A2+, HCMV-seropositive donors tested (examples in fig. 1B), but 
not in HCMV-seronegative donors, indicating this epitope to be the most 
immunodominant CTL epitope. T cells restricted to pp65 120–128, also presented by 
HLA-A*0201, were detected in 5/10 donors (examples in fig. 1B). Furthermore, 
immunodominance was determined for two epitopes presented by HLA-B*0702 
(pp65 417–426, pp65 265–275) as can be seen in fig. 1C. Apart from these 
immunodominant epitopes, we also noticed six CTL epitopes which occurred in less 
than 50% of donors tested (A*0201: MLNIPSINV, VLEETSVML; A*0301: 
TTVYPPSSTAK; A*6801: FVFPTKDVALR; B*44: QEFFWDANDIY, SEHPTFTSQY). 
For several peptides, including pub-lished CTL epitopes [15; 20; 24], no CTL 
response could be detected in the HCMV-seropositive donors tested (table 1).  
 
 
Table 1. Summary of CTL epitopes analysed 
HLA Protein Position Sequence Reference n c 
Tetramer 
n c 
IFNγ
A*0101 pp65  363-373 YSEHPTFTSQY d [26] 14/15 n.t.
 pp50 245-253 VTEHDTLLY d [17] 8/10 n.t.
 pp50 274-253 RGDPFDKNY predicted 0/6 n.t.
A*0201 pp65 495-503 NLVPMVATV d [29] 13/13 n.t.
 pp65 120-128 MLNIPSINV [28] 5/10 n.t.
 pp65 522-530 RIFAELEGV [24] 0/6 n.t.
 IE1 316-324 VLEETSVML [22] 2/6 n.t.
A*0301 pp150 945-955 TTVYPPSSTAK [26] 1/12 n.t.
A*1101 pp65 16-24 GPISGHVLK [20] 0/5 n.t.
 pp65 501-509 ATVQGQNLK [24] 0/3 n.t.
A*2402 pp65 341-349 QYDPVAALF [15] 0/6 n.t.
A*6801 pp65 186-196 FVFPTKDVALR [26] 1/5 n.t.
 pp65 183-191 TSAFVFPTK b this paper              see Table 5
 pp150 794-802 VTSTPVQGR predicted 0/5 n.t.
A*69 pp65 86-94 EVENVSVNV a this paper              see Table 5
B*0702 pp65 417-426 TPRVTGGGAM d [20] 11/13 n.t.
 pp65 265-275 RPHERNGFTVL d [26] 10/11 n.t.
 IE1 310-317 RVLCCYVL predicted 0/19 n.t.
B*13 pp65 211-219 TRATKMQVI a this paper              see Table 5
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B*1501 pp65 355-363 LLLQRGPQY predicted 0/3 0/3
 pp65 73-81 NQLQVQHTY predicted 0/3 0/3
 pp65 361-369 PQYSEHPTF predicted 0/3 0/3
 pp65 505-513 GQNLKYQEF predicted 0/3 0/3
 pp65 502-510 TVQGQNLKY predicted 0/3 0/3
 pp65 319-327 LLMNGQQIF predicted 0/3 0/3
 pp65 74-82 QLQVQHTYF predicted 0/3 0/3
 pp65 215-223 KMQVIGDQY [24] 0/3 0/3
 pp65 173-181 NQWKEPDVY predicted n.t. 0/3
 pp65 223-231 YVKVYLESF predicted n.t. 0/3
B*2705 pp65 539-547 RRRHRQDAL predicted 0/2 0/2
 pp65 373-381 YRIQGKLEY predicted n.t. 0/2
 pp65 264-272 MRPHERNGF predicted n.t. 0/2
 pp65 39-47 TRLLQTGIH predicted n.t. 0/2
 pp65 257-265 TRNPQPFMR predicted n.t. 0/2
 pp65 358-366 QRGPQYSEH predicted n.t. 0/2
 pp65 418-426 PRVTGGGAM predicted n.t. 0/2
 pp65 3-11 SRGRRCPEM predicted n.t. 0/2
B*40 pp65 42-50 KEVNSQLSL a this paper              see Table 5
B*44 pp65 511-521 QEFFWDANDIY predicted 0/10 1/10
 pp65 267-275 HERNGFTVL [24] 0/10 0/10
 pp65 232-240 CEDVPSGKL [24] 0/10 0/10
 pp65 364-373 SEHPTFTSQY [24] 1/10 5/10
B*51 pp65 116-123 LPLKMLNI a this paper              see Table 5
 pp65 114-123 YALPLKMLNI a this paper              see Table 5
a/b Epitopes were identified by intracellular IFNγ staining(a) or tetramer staining(b) in donors 
who had reacted to corresponding long peptides (see Table 4). n.t. = not tested 
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Figure 1. Representative tetrameric analyses for alleles HLA-A*0101 (A), HLA-A*0201 (B) and 
HLA-B*0702. PBMCs were stained with HCMV-tetramer-PE, CD8-PerCP and CD19-FITC. 
Percentages refer to tetramer+ T cells within the CD8+ population. (A) Binding to HLA-A*0101 
tetramers YSEHPTFTSQY (pp65 363–373) and VTEHDTLLY (pp50 245–253) in same donors. (B) 
Binding of HLA-A*0201 NLVPMVATV-tetramer (pp65 495–503) and MLNIPSINV-tetramer (pp65 120–
128) in HLA-A2 positive donors. (C) Parallel detection of T cells binding to HLA-B*0702 tetramers 
TPRVTGGGAM (pp65 417–426) and RPHERNGFTVL (pp65 265–275). 
 
 
Investigation of hierarchy among immunodominant epitopes 
Frequencies of CTLs specific for immunodominant epitopes were compared in 
donors having at least two of the alleles HLA-A1, -A2 or -B7 in common. As can be 
seen in table 2, T cells specific for different CTL epitopes were detected in parallel. 
Moreover, strong responses to one epitope did not prevent the detection of lower 
frequencies of CTLs specific for other epitopes, as can be seen in donor 5 and donor 
16. The detection limit of tetramer staining is described as 0.01%. Nethertheless, in 
two donors we observed distinct CD8+ T cell populations lower than 0.01%. Overall, 
no clear hierarchy was observed in that CTL populations specific for several 
immunodominant T cell epitopes in parallel were frequently observed. Therefore, 
codominance among these epitopes, especially for B*0702 restricted ones, appeared 
to be a common feature. 
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Table 2. Frequencies of immunodominant pp65 epitopes in HCMV seropositive donors as 
determined by tetramer staining 
Donor HLA type of 
donors tested  
YSEHPTFTSQY 
(A*0101)
NLVPMVATV 
(A*0201)
TPRVTGGGAM 
(B*0702) 
RPHERNGFTVL 
(B*0702)
BD 1 A1 A3 B7 B8 0.01 <0.01 0.12
BD 2 A1 A28 B7 B49 0.02 0.02 0.08
BD 3 A1 A2 B8 B35 0.01 0.70  
BD 4 A2 B7 B13 0.85 0.81 0.08
BD 5 A1 B7 B55 0.01 2.02 0.16
BD 8 A11 A24 B7 0.21 0.69
BD 9 A2 A3 B7 B51 0.03 1.31 0.42
BD 10 A1 A2 B18 B62 0.04 0.03  
BD 11 A1 A23 B7 B49 0.07 <0.01 <0.01
BD 13 A3 B7 B35 1.10 0.14
BD 15 A3 A11 B7 B62 0.03 0.03
BD 16 A1 A2 B8 B44 0.32 1.26  
BD 17 A2 A3 B7 B35 0.01 0.29 0.57
 
 
Functional and phenotypic characterization of CD8+ T cells restricted to 
immunodominant epitopes 
CD8+ T cells specific for immunodominant epitopes were analysed for their functional 
capacity to produce IFNγ. Therefore, tetramer staining in combination with 
intracellular IFNγ staining was performed with PBMCs of donors already tested with 
the tetramers. As shown in table 3, tetramer+ CD8+ T cells recognizing epitopes 
presented by HLA-A*0101, -A*0201 or -B*0702 were often capable of producing 
IFNγ. Surprisingly, no IFNγ secretion by T cells specific for the immunodominant 
epitope pp65 363–373 presented by HLA-A*0101 could be detected in three 
independent experiments.  
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Table 3. IFNγ responses to immunodominant HCMV epitopes 
HLA tested Protein/position Sequence n a
A*0101 pp65 363-373 YSEHPTFTSQY 0/6
 pp50 245-253 VTEHDTLLY 3/6
A*0201 pp65 495-503 NLVPMVATV 7/8
B*0702 pp65 417-426 TPRVTGGGAM 7/9
 pp65 265-275 RPHERNGFTVL 7/9
a n refers to number of individuals showing IFNγ response against this epitope/total number 
of individuals with corresponding alleles tested. 
 
 
HCMV tetramer+ CD8+ T cells were investigated for their phenotypic attributes with 
several surface markers; CCR7, CD45RA, CD45RO, CD27, CD57, CD62L and CD28 
(Figure 2). CTLs specific for HCMV antigens were analysed by tetramers pp65 495-
503 (A*0201), pp65 415-429 and pp65 265-275 (both B*0702). CD8+ T cells detected 
by HCMV tetramers expressed CD45RA+ CCR7- CD27+ and CD28low and found to 
represent so-called TEMRA cells (CD45RA+ effector memory T cells) which display 
phenotypic features that are intermediate between naive and effector T cells [36; 37]. 
Similar phenotypes have already been described for circulating memory CTLs 
specific for other persisting viruses such as EBV [38]. The low expression of CD28 
indicates that these cells are senescent reflecting frequent restimulation in vivo [39].  
After polyclonal expansion cells were used in a 51Cr-release assay to analyse their 
ability to lyse antigen presenting target cells. Peptide NLVPMVATV (HCMV pp65495-
503) was loaded on either TAP-deficient HLA-A*0201 positive T2 cells, or on human 
LCL HLA-A*0201 Awell cells. In both cases it was possible to provoke lysis of the 
target cells measured by release of 51chromium in the supernatant. Used effector 
NLVPMVATV specific T cells were able to kill antigen presenting target cells with a 
specific lysis of 40%-80% (Figure 3). No lysis was observed if effector cells were 
incubated with targets either loaded with irrelevant peptide ILKEPVHGV-peptide 
(HIV-1 RT476-484) or without peptide.  
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Figure 2. Investigation of phenotypic attributes of HCMV tet+ cells. PBMCs were stained with 
HCMV tetramer-PE, CD8-PerCP and phenotypic marker labelled to FITC. Percentages present 
tetramer+/marker+ T cells within the CD8+ population. 
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Figure 3. Specific lysis by HCMV pp65495-503 specific T cells measured by 51Cr release. Targets 
cells were loaded with either NLVPMVATV-peptide (HCMV495-503), ILKEPVHGV-peptide (HIV-1 RT476-
484) or without peptide.  
 
 
T cell receptor downregulation after peptide activation 
HLA/peptide complexes (tetramers) are nice tools for the for detection of antigen-
specific CD8+ T cells but several questions have been raised about functional 
significance of the observed antigen-specific T cells [40-43]. Studies in a murine 
model of lymphocytic choriomeningitis virus (LCMV) infection in which CD4+ T cell 
help was deficient revealed that the circulating tetramer-staining CD8+ cell population 
was functionally defective and unable to mediate protection [43]. To address this 
problem, Appay et al. developed a method that combines the precision of tetramer 
quantification with intracellular cytokine staining to get detailed information about 
individual CD8+ T cell function. Combination of these two assays raised a problem: 
activation procedures to stimulate cytokine production also leads to downregulation 
of the T-cell receptor (TCR) [44], with which the tetrameric complexes interact. Figure 
4 shows staining of peripheral blood mononuclear cells (PBMCs) from three healthy 
HCMV positive donors with known HLA type with different HCMV tetramers. 
Stimulation of the cells with peptide led to significant downregulation of the TCR 
assessed by the intensity of tetramer staining in a CD8+ population (Figure 4, left 
panel). This problem can be solved by tetramer staining of the cells before activation 
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(Figure 4, right panel). However, PBMCs stained with tetramers before activation 
showed also reduced levels of tetramer+ CD8+ T cells compared with levels of 
antigen-specific CD8+ T cells detected in a single tetramer staining (data not shown). 
This is probably due to internalization of tetramers [45]. 
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Figure 4. Tetramer staining and cell activation. PBMCs from HCMV-seropositive donors were 
stained with tetramer either after incubation with specific HCMV peptide or before addition of the 
activators. Percentages of tetramer positive cells within the CD8+ population are shown. (+) Donors 
are positive for the HLA-molecule given on the left side. (-) Donors are negative for the HLA-molecule 
given on the left side. 
 
 
Identification of novel CD8 T cell epitopes 
Among several strategies for identification of CD8 T cell epitopes, both verification of 
predicted epitopes and epitope identification by large-scale screens with partially 
overlapping 15–20mer peptides [39] have been successfully employed. As these two 
strategies may complement each other, we utilized both for identification of CD8 T 
cell epitopes. In this context, the nature of non-CD4 T cell mediated reactions 
observed during screens with 15–20mer peptides was further investigated as to their 
identity as CD8 T cell responses directed against shorter peptides included in longer 
ones, probably after in vitro processing. Non-CD4-mediated reactions were observed 
after stimulation of PBMCs from 14 HCMV-seropositive donors, but not with PBMCs 
from HCMV-seronegative donors. Altogether, IFNγ-producing non-CD4 T cells 
specific for 14 peptides from pp65 and IE-1 were detected (data not shown). As some 
of these long peptides contained known CD8 T cell epitopes, we assumed that the 
observed non-CD4-mediated T cell reactions were CD8 T cell responses. Therefore, 
considering the MHC class I alleles of reacting donors, potential CD8 T cell epitopes 
were selected from 15–20mer peptides according to peptide motifs of HLA allotypes 
[32]. Depending on the availability of the heavy chains of MHC class I alleles for 
tetramer synthesis, which can be restrictive, short peptides were either used for 
tetramer synthesis and tetramer staining plus anti CD8-PerCP antibody, or tested for 
their capacity to give rise to specific CD8 T-cell-mediated reactions by intracellular 
IFNγ-staining plus CD8-PerCP antibody. Peptides capable of eliciting non-CD4 T-
cellmediated reactions and corresponding CD8 T cell epitopes are summarized in 
table 4. Potential CD8 T cell epitopes were tested in donors who had reacted to the 
corresponding long peptides and who were positive for the potentially restricting 
allele (one donor for each long peptide except two donors for pp65 109–123). IFNγ-
producing CD8 T cells were observed in one donor for each novel CD8 T cell 
epitope, respectively. This refers to peptides pp65 86–94 (EVENVSVNV, potentially 
A*69 restricted), pp65 116–123 (LPLKMLNI) and pp65 114–123 (YALPLKMLNI, both 
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potentially B*51 restricted), pp65 211–219 (TRATKMQVI, potentially B*13 restricted) 
and IE-1 42–50 (KEVNSQLSL, potentially B*40 restricted), while restriction could be 
assessed unequivocally by tetramer staining for peptide pp65 183–191 
(TSAFVFPTK) for which an A*6801 tetramer had been produced. 
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Table 4. Non-CD4 reactions to 15-20mer peptides from pp65 and IE-1 and CD8 reactions to 
corresponding 8-11mer peptides.  
 
Peptide sequence 
 
Protein/Position 
(Potential) MHC 
class I restriction Reference
 pp65  
ISVLGPISGHVLKAV  
        GPISGHVLK 
12-26 
16-24 
 
A*1101 [20]
EVENVSVNVHNPTGR 
EVENVSVNV a  
86-100 
86-94 
 
A*69 this paper
MSIYVYALPLKMLNI 
                  LPLKMLNI a 
             YALPLKMLNI a 
109-123 
116-123 
114-123 
 
B*51 
B*51 
this paper
this paper
PLKMLNIPSINVHHY  
                IPSINVHHY  
117-131 
123-131 
 
B*3501 [19]
VYYTSAFVFPTKDVA 
         TSAFVFPTK b 
180-194 
183-191 
 
A*6801 this paper
TSAFVFPTKDVALRH  
       FVFPTKDVALR 
            FPTKDVAL 
183-197 
186-196 
188-195 
  
A*6801 
B*3502 
[26]
VCSMENTRATKMQVI 
                TRATKMQVI a 
205-219 
211-219 
 
B*13 this paper
GPQYSEHPTFTSQYRI 
        YSEHPTFTSQY  
360-375 
363-373 
 
A*0101 [26]
HPTFTSQYRIQGKLE  
       FTSQYRIQGKL 
366-380 
369-379 
 
A*2402 [26]
 IE1  
QTMLRKEVNSQLSLG 
              KEVNSQLSL a 
37-51 
42-50 
 
B*40 this paper
RVLCCYVLEETSVMLAKRPLI 
                VLEETSVML 
310-330 
316-324 
 
A*0201 [22]
a Specific CD8 T cells were detected by intracellular IFNγ staining. 
b Specific CD8 T cells were detected by tetramer staining. 
Novel CD8 T cell epitopes with their position in protein and potential MHC class I restriction 
are printed in italic.  
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Responses to known and novel CD4 T cell epitopes 
PBMCs of 30 healthy HCMV-seropositive and 5 healthy HCMV-seronegative donors 
were stimulated with 15 peptide pools each containing three to five 15–20mer 
peptides from pp65 or IE-1 which represented potential HLA-DR epitopes. Reactivity 
to peptides was assessed by intracellular IFNγ staining plus CD4-FITC antibody. 
Peptide specificity of reactions observed after stimulation with peptide pools was 
determined by splitting of pools and testing reactions to single peptides. None of five 
seronegative donors showed any specific reaction after stimulation with peptide 
pools. Among 30 seropositive donors, 25 showed CD4 T cell reactions to at least one 
peptide. Most donors specifically reacted to one or two peptides; reactions to more 
than three peptides in a single donor were observed less frequently. Altogether, 15 
peptides from pp65, but none from IE-1, were able to elicit CD4 reactions. Many of 
these peptides have previously been reported to constitute CD4 T cell epitopes and 
are listed in table 5. However, four of these peptides have not been described as 
CD4 T cell epitopes so far, pp65 109–123 (MSIYVYALPLKMLNI), pp65 191–205 
(KDVALRHVVCAHELV), pp65 269–283 (RNGFTVLCPKNMIIK) and pp65 339–353 
(LRQYDPVAALFFFDI). HLA-DR restriction for novel CD4 T cell epitopes was 
assigned according to overlapping expression of alleles in reacting donors. If no 
potential HLA-DR restriction could be assigned, as was the case for peptides pp65 
191–205 and pp65 269–283, the number of reacting donors out of 30 HCMV-
seropositive donors is given in brackets. In addition to determination of CD4 T cell 
epitopes, immunodominance values were evaluated for each of the CD4 T cell 
epitopes investigated in this study.  
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Table 5. CD4 T cell reactions to 15mer peptides from pp65. 
(Potential) DR 
restriction 
Peptide 
position Peptide sequence Reference 
nb
DRB1*01 117-131a (1) PLKMLNIPSINVHHY [25] 4/12 
DRB1*01 166-180 LAWTRQQNQWKEPDV [21; 25] 1/12 
DRB1*01  510-524a (3) YQEFFWDANDIYRIF [18; 21; 25] 6/12 
DRB1*03 510-524a (3) YQEFFWDANDIYRIF [18; 21; 25] 3/4
DRB1*01  512-524a (3) EFFWDANDIYRIF [18; 21; 25] 1/12 
DRB1*03 512-524a (3) EFFWDANDIYRIF [18; 21; 25] 3/4
DRB1*03 250-264 VEEDLTMTRNPQPFM [25] 1/4 
DRB1*04   283-299a (1) KPGKISHIMLDVAFTSH [21; 25] 3/6 
DRB1*07 283-299a (1) KPGKISHIMLDVAFTSH [21; 25] 3/5
370-384 TSQYRIQGKLEYRHT [25] 4/6 DRB1*04 DRB1*13 
370-384 TSQYRIQGKLEYRHT [25] 4/10
DRB1*07 109-123 MSIYVYALPLKMLNI this paper 2/5 
DRB1*07 180-194 VYYTSAFVFPTKDVA [25] 2/5 
DRB1*07 339-353 LRQYDPVAALFFFDI this paper 3/5 
DRB1*11 360-375 GPQYSEHPTFTSQYRI [18; 21; 23; 25] 5/12 
DRB1*11 366-380 HPTFTSQYRIQGKLE [18; 21; 23; 25] 6/12 
DRB1*13 366-380 HPTFTSQYRIQGKLE [18] 1/10
DRB1*15 39-53 TRLLQTGIHVRVSQP [21; 23; 25] 4/5 
not assigned 191-205 KDVALRHVVCAHELV this paper (2)
not assigned 269-283 RNGFTVLCPKNMIIK this paper (1)
a Peptides with a potential DR restriction(s) that can not account for all of the observed 
responses are marked. The number of additional reacting donors negative for the potentially 
restricting DR allele(s) is given in brackets. 
b n refers to the number of individuals showing responses against this epitope/ total number 
of individuals with corresponding allele tested 
Novel CD4 T cell epitopes with potential HLA-DR restriction are printed in italic. 
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Discussion 
 
We investigated the CD8 and CD4 T cell responses of 67 HCMV-seropositive donors 
against reported and predicted HCMV-derived peptides. We identified six new HLA 
class I restricted and four new HLA class II restricted epitopes, and confirmed 
previously reported epitopes [15; 17; 20; 22; 24; 26; 28; 29]. We could determine 
immunodominance, as defined above, for each of two epitopes restricted to HLA-A* 
0101 and HLA-B*0702, respectively, and for one HLA-A*0201 restricted epitope. For 
HLA-A*0201 and for -B*0702, the detected immunodominant epitopes have their 
origin in the same protein and were detected with similar frequencies in different 
donors. In view of this observation, we analysed the hierarchy among the frequently 
recognized epitopes detected in donors carrying HLA-A1, -A2 and/or -B7. 
Surprisingly, no clear hierarchy was observed among these epitopes tested. The 
observation that two different epitopes derived from the very same antigen and 
presented by the same HLA class I molecule appear to be codominant is in sharp 
contrast to hierarchy studies of viral CTL epitopes in mouse models [46]. The epitope 
pp65 364–373 was predicted according to the HLA-B*4402 motif. However, donors 
were only typed with low resolution (HLA-B44). Earlier reports suggested, that this 
epitope is restricted to HLA-B*4403 [24]. HLA-B*4402 and -B*4403 are two major 
HLA-B*44 subtypes in white individuals [47; 48] and HLA-B*4403 is the most frequent 
HLA-B*44 subtype in Japanese individuals [49-51]; the peptide repertoires presented 
by both subtypes are overlapping by 95% [52]. Furthermore, we were able to define 
six new CD8 T cell epitopes. Restriction of these novel epitopes could be determined 
unequivocally by tetramer staining for peptide pp65 183–191, which is A*6801 
restricted. Studies aiming at the unambiguous determination of the five remaining 
epitopes restriction and at confirming these peptides identities as natural CD8 T cell 
epitopes from HCMV are currently in progress. Furthermore, due to rareness of 
restricting alleles, immunodominance values of individual novel CD8 T cell epitopes 
have not yet been assessed but are the subject of ongoing studies. This approach for 
identification of novel CD8 T cell epitopes from rare alleles may prove valuable for 
complementing other strategies, such as verification of predicted epitopes for 
frequent alleles. We identified four novel CD4 T cell epitopes. However, the identity of 
these peptides as natural CD4 T cell epitopes still needs to be confirmed, and their 
HLA-DR restriction has to be assessed unequivocally. Both aspects are the subject 
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of ongoing studies. All other peptides listed in table 5 have been reported previously 
as CD4 T cell epitopes [25]. 
In most cases, HLA-DR restriction of known CD4 T cell epitopes was in accordance 
with earlier reports [18; 21; 23; 25]. However, this was not the case for peptide pp65 
370–384, where DRB1*04 and/or DRB1*13 restriction seems to be more plausible 
than the proposed DRB1*03 restriction. The reduction of immunodominance of 
peptide pp65 512–524 as compared with peptide pp65 510–524 on DRB1*01 (6/12 
vs. 1/12) but not on DRB1*03 (3/4 vs. 3/4) may be explained by the binding motif of 
DRB1*01. DRB1*01 has a preference for hydrophobic residues in positions 1, 4, 6 
and 9 which are provided by peptide pp65 510–524 but not by peptide pp65 512–
524. On the other hand, peptide binding to DRB1*03 favours aspartate in position 4, 
which is supplied by D516 and is therefore independent of the first two amino acids in 
peptide pp65 510–524. Immunodominance values were approximately equal to those 
determined in the study of [25]. In general, immunodominance values of CD4 T cell 
epitopes are considerably lower than those of CD8 T cell epitopes, some of which are 
capable of inducing responses in up to 100% of donors. In contrast to CD8 T cell 
epitopes, responses on one allele are not focused on a single epitope but seem to be 
spread over several epitopes, indicating a preference for codominance. In view of this 
fact, CD4 T cell epitopes with high codominance values were identified for nearly all 
frequent DR alleles. Such CD4 T cell epitopes should be valuable for therapy and 
vaccine development. 
The observed CD4 and CD8 T cell responses were investigated for their interrelation. 
To this end, number and strength of CD4 and CD8 T cell responses were compared 
in 11 donors already tested. No obvious interrelationship could be assessed. CD8 T 
cell responses to various numbers of peptides and of varying strengths could be 
observed in donors independent of number and strength of CD4 T cell responses 
and even in donors in which no CD4 T cell responses could be observed. Reactions 
restricted to HLA-DQ and -DP were not the topic of this study.  
In summary, we characterized six dominant CTL epitopes from both pp65 and IE-1. 
Furthermore, four new TH epitopes from pp65 were found. For novel and reported 
CD8 T cell epitopes, as well as for CD4 T cell epitopes, levels of immunodominance 
and codominance were determined.  
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3 Results and Discussion, Part 2: Tumor Associated 
Antigens 
 
3.1 Unexpected abundance of HLA class II presented peptides in 
primary renal cell carcinomas 
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Summary 
 
In the absence of inflammation, expression of MHC class II molecules is mainly 
restricted to cells of the immune system. To our surprise, we were able to isolate and 
characterize hundreds of class II peptides directly from primary dissected solid 
tumors, especially from renal cell carcinomas. Infiltrating monocytes expressed MHC 
class II molecules as well as tumor cells and in addition, tumor cells showed 
upregulation of several interferon gamma-induced gene products. Our list of identified 
peptides contains ligands from several tumor-associated antigens, including IGFBP3 
and MMP7. The latter bound promiscuously to HLA-DR molecules and were able to 
elicit CD4+ T cell responses in healthy donors. Thus, our direct approach will rapidly 
expand the limited number of T helper epitopes from tumor associated antigens. 
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Introduction 
 
CD4+ helper T cells play an important role in orchestrating the effector function of 
anti-tumor T cell responses [1] and for this reason the identification of CD4+ T cell 
epitopes derived from tumor associated antigens (TAA) has recently been a major 
focus of attention [2; 3]. Even in the absence of cytotoxic T lymphocyte (CTL) effector 
cells, helper T cells in the mouse can inhibit tumor angiogenesis via IFNγ [4] and 
counteract tumor progression via the induction of an Ab response [5]. In contrast to 
HLA class I ligands, only a small number of class II ligands of TAA have been 
described. Since HLA class II molecules are constitutively presented on cells of the 
immune system alone [6], the possibility of isolating class II peptides directly from 
primary tumors as opposed to class I ligands [7] has not been considered viable. 
Therefore, numerous strategies to target antigens into the class II processing 
pathway of antigen presenting cells (APCs) have been described, for example the 
incubation of APCs with the antigen of interest to enable it to be taken up, processed 
and presented [8]. 
In order to identify HLA class II ligands from TAA for their use in peptide-based 
immunotherapy, we attempted to isolate HLA-DR-presented peptides directly from 
dissected solid tumors, in particular from renal cell carcinoma (RCC), which have 
been reported to be able to express class II molecules [9]. Even if the majority of 
tumor cells were class II negative, with state-of-the-art mass spectrometers it should 
be possible to identify class II peptides from minimal numbers of tumor cells, from 
infiltrating leukocytes possibly cross-presenting TAA, and from stromal cells.  
The reasons for concentrating on RCC are the following: Around 150,000 people 
worldwide are affected by RCC each year, resulting in approximately 78,000 deaths 
per annum [10]. If metastasis is diagnosed, the one-year survival rate decreases to 
approximately 60% [11], underlining the dissatisfactory therapeutic situation. 
Because RCC seems to be an immunogenic tumor, as indicated by the existence of 
tumor-reacting and tumor-infiltrating CTL [12], clinical trials have been initiated to 
develop peptide-based anti-tumor vaccinations. However, due to the lack of helper T 
cell epitopes from TAA, molecularly defined vaccines usually comprise class I ligands 
only. 
We were able to isolate class II ligands from ten RCC, three colorectal carcinomas 
(CCA) and one transitional cell carcinoma (TCC, urothelial carcinoma). Selected 
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ligands of TAA promiscuously binding to HLA-DR molecules were found to be 
recognized by CD4+ T cells. 
 
Material and Methods 
 
 
MHC class II immunohistology 
Tumors were fixed in 4% phosphate-buffered formaldehyde, embedded in paraffin, 
stained with hematoxylin-eosin and examined by light microscopy. Diagnosis of the 
RCC was carried out according to routine histopathological and immunohistological 
investigations [13]. 
For immunohistological detection of MHC class II molecules or CD68 molecules, 
respectively, 5 µm paraffin-embedded tissue sections were pretreated with 10 mM 
citrate buffer, pH 6, followed by incubation either with a mouse anti-HLA-DR alpha-
chain mAb (clone TAL.1B5, 1:50) or CD68 Ab (Clone PGM1, 1:50 ) (DAKO, 
Hamburg, Germany) or mouse IgG1 (2 µg/ml, BD Biosciences Pharmingen, San 
Diego, USA) and visualized using the Ventana iView DAB detection kit (Nexes 
System, Ventana Medical Systems, Illkirch, France). Tissue sections were 
counterstained with hematoxylin and finally embedded in Entellan. 
 
Elution and molecular analysis of HLA-DR bound peptides 
Frozen tumor samples were processed as previously described [14] and peptides 
were isolated according to standard protocols [15] using the HLA-DR specific mAb 
L243 [16]. 
Natural peptide mixtures were analyzed by a reversed phase Ultimate HPLC system 
(Dionex, Amsterdam, Netherlands) coupled to a Q-TOF I mass spectrometer 
(Waters, Eschborn, Germany), or by a reversed phase CapLC HPLC system coupled 
to a Q-TOF Ultima API (Waters) as previously described [17]. Fragment spectra were 
analyzed manually and automatically. 
 
Gene expression analysis by high-density oligonucleotide microarrays 
RNA isolation from tumor and autologous normal kidney specimens as well as gene 
expression analysis by Affymetrix Human Genome U133 Plus 2.0 oligonucleotide 
microarrays (Affymetrix, Santa Clara, CA, USA) were performed as described 
previously [18]. Data were analyzed with the GCOS software (Affymetrix). Pairwise 
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comparisons between tumor and autologous normal kidney were calculated using the 
respective normal array as baseline. For RCC149 and RCC211 no autologous 
normal kidney array data were available. Therefore, pooled healthy human kidney 
RNA was obtained commercially (Clontech, Heidelberg, Germany) and used as the 
baseline for these tumors. 
 
Maturation of DCs 
DCs were prepared using blood from healthy donors. Briefly, PBMCs were isolated 
using standard gradient centrifugation (Lymphocyte Separation Medium, PAA 
Laboratories GmbH, Pasching, Austria) and plated at a density of 7 × 106 cells/ml in 
X-Vivo 15 medium. After 2 hours at 37°C, non-adherent cells were removed and 
adherent monocytes cultured for 6 days in X-Vivo medium with 100 ng/ml GM-CSF 
and 40 ng/ml IL-4 (AL-ImmunoTools, Friesoythe, Germany). On day 7 immature DCs 
were activated with 10 ng/ml TNF-α (R&D Systems, Wiesbaden, Germany) and 20 
µg/ml poly(IC) (Sigma Aldrich, Steinheim, Germany) for 3 days. 
 
Generation of antigen-specific CD4+ T cells 
106 PBMCs per well were stimulated with 2 × 105 peptide pulsed (5 µg/ml) 
autologous DCs. Cells were incubated in 96-well plates (7 wells per donor and per 
peptide) with T-cell medium: supplemented RPMI 1640 in the presence of 10 ng/ml 
IL-12 (Promocell, Heidelberg, Germany). After 3 to 4 days of co-incubation at 37°C, 
fresh medium with 80 U/ml IL-2 (Proleukin, Chiron Corporation, Emeryville, CA, USA) 
and 5 ng/ml IL-7 (Promocell) was added. Restimulations were done with autologous 
PBMCs plus peptide every 6 to 8 days. 
 
Intracellular IFNγ staining 
After 3 and 4 rounds of stimulation, PBMCs were thawed, washed twice in PBS, 
resuspended at 107 cells/ml in T-cell medium and cultured overnight. On the next 
day, PBMCs, pulsed with 5 µg/ml peptide, were incubated with effector cells in a ratio 
of 1:1 for 6 h. Golgi-Stop (Becton Dickinson, Heidelberg, Germany) was added for 
the final 4 h of incubation. 
Cells were analyzed using a Cytofix/Cytoperm Plus kit (Becton Dickinson) and CD4-
FITC- (Immunotools), IFNγ-PE- and CD8-PerCP clone SK1-antibodies (Becton 
Dickinson). For negative controls, cells of seven wells were pooled and incubated 
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either with irrelevant peptide or without peptide, respectively. Stimulation with 
PMA/Ionomycin was used for positive control. Cells were analyzed on a three-color 
FACSCalibur (Becton Dickinson). 
 
Results and Discussion 
 
HLA class II expression by RCC 
Under normal, non-inflammatory conditions class II molecules should only be 
expressed by cells of the hematopoietic system and by the thymic epithelium [6]. The 
situation changes during inflammation. MHC II expression can be induced in most 
cell types and tissues by IFNγ [19]. As RCC incidence is often accompanied by 
inflammatory events [20; 21], class II molecules are indeed expressed in the vicinity 
of or by tumors, as has been reported [22]. 
We analyzed HLA class II expression of ten RCC specimens comprising histological 
clear cell and papillary renal carcinoma by immunohistochemical staining and found 
that all investigated samples revealed class II positive tumor cells. As exemplified in 
Figure 1A, a pronounced HLA class II expression was often detected at the margin of 
the tumor. In these areas we observed a close spatial correlation of HLA positive 
tumor cells with tumor infiltrating immune cells as illustrated by the visualization of 
CD68-positive macrophages in a serial tissue section (Figure 1B). In RCC revealing a 
more papillary architecture, the expression of HLA class II molecules was more 
evenly distributed throughout the tumor (Figure 1C, E, G). The comparison of the 
HLA class II and CD68 immunohistochemical staining patterns in serial tissue 
sections clearly demonstrates that in addition to macrophages, tumor cells also 
express HLA class II (Figure 1C, D and E, F). It has been shown that IFNγ producing 
CD4+ Th1 cells as well as NK cells infiltrate RCC [23]. As class II positive tumor cells 
were found predominantly in outer parts of dissected tumors, one could speculate 
that leukocytes attracted by the tumor produce IFNγ which acts on neighboring 
malignant cells. 
Additionally, we investigated class II expression by comparative gene expression 
analysis using oligonucleotide microarrays. With this technique we were able to 
asses the overall class II expression in the dissected tumors regardless of the 
expressing cell types. We analyzed differential expression in four tumors, RCC149, 
RCC180 RCC190, and RCC211, compared with normal reference kidney. In all four 
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tumors HLA class II genes were overexpressed (Table 1). One possible reason for 
this might be an induced expression by IFNγ and for this reason we looked for other 
genes known to be upregulated by interferons [24]. Interestingly, a considerable 
number of such genes were found to be overexpressed in one or more tumor 
samples. Table 1 shows interferon-inducible genes which were upregulated 
reproducibly in all four samples, in accordance with our earlier findings [25]. Among 
them are LMP2, LMP7, and MECL1 - proteins which are exchanged against 
constitutive proteasomal subunits to form the immunoproteasome, a hallmark 
process in an interferon-rich environment. Additionally, IFNγ was directly assessed 
by quantitative real-time RT PCR (TaqMan). The tumors displayed in Table 1 showed 
a 5- to 60-fold IFNγ mRNA overexpression compared with their autologous normal 
RNA samples (data not shown). Thus our results indicate that IFNγ might play an 
important role in RCC and be the reason for abundant class II expression. 
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Figure 1: Expression of HLA class II molecules in RCC of three patients. Whereas in the tumor of 
patient RCC132 the HLA positive cells were preferably localized at the margin (A, B) the HLA class II 
expression patterns of the tumors from patient RCC190 and RCC211 revealing a more papillary 
structure were more evenly spread (C, E, G). The visualization of CD68+ macrophages (B, D, F) in 
serial tissue sections illustrates a close spatial relationship of tumor-infiltrating mononuclear immune 
cells and HLA II expressing tumor cells. Incubation with mouse IgG instead of specific antibodies 
consistently revealed negative staining results (H). Capital T marks the tumor. 
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Table 1: mRNA expression of interferon-inducible genes. 
Expression in tumor samples was compared with autologous normal kidney (RCC180, 
RCC190) or pooled healthy kidney (RCC149, RCC211). All genes showed an "increase" in 
the change-call algorithm of the GCOS software for all four tumors and have been described 
as interferon-inducible. 
-fold overexpression tumor vs. normal Gene  
Symbol 
Entrez 
GeneID 
Gene Title 
RCC149 RCC180 RCC190 RCC211 
HLA-DPA1 3113 major histocompatibility 
complex, class II, DP alpha 1
3.5 3.7 4.9 13.9 
HLA-DPB1 3115 major histocompatibility 
complex, class II, DP beta 1 
2.6 2.5 2.8 14.9 
HLA-DQB1 3119 major histocompatibility 
complex, class II, DQ beta 1 
4.3 4.0 6.5 5.3 
HLA-DRB1 3123 major histocompatibility 
complex, class II, DR beta 1 
1.2 1.9 2.8 4.3 
CXCL10 3627 chemokine (C-X-C motif) 
ligand 10 
1.1 3.2 10.6 24.3 
FCGR1A 2209 Fc fragment of IgG, high 
affinity Ia, receptor for (CD64)
6.5 2.6 12.1 29.9 
IFI16 3428 interferon, gamma-inducible 
protein 16 
8.6 3.0 4.3 11.3 
IFI44 10561 interferon-induced protein 44 2.8 1.4 2.5 2.8 
OAS1 4938 2',5'-oligoadenylate 
synthetase 1, 40/46kDa 
3.5 2.3 2.6 5.3 
PSMB8 5696 proteasome subunit, beta 
type, 8 (LMP7) 
2.6 4.3 6.1 6.5 
PSMB9 5698 proteasome subunit, beta 
type, 9 (LMP2) 
4.3 7.5 6.5 16.0 
PSMB10 5699 proteasome subunit, beta 
type, 10 (MECL1) 
3.2 2.5 5.3 13.0 
SP100 6672 nuclear antigen Sp100 4.0 1.1 1.5 2.8 
TAP1 6890 transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
2.5 2.8 6.5 8.0 
VCAM1 7412 vascular cell adhesion 
molecule 1 
5.7 5.3 3.2 12.1 
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HLA-DR ligands isolated from dissected carcinomas 
Class II peptides from solid tumors have so far not been isolated and identified. We 
analyzed ten different RCC, three CCA and one TCC and were able to isolate HLA-
DR ligands from all samples, 452 peptides in total (Table 2). Table 3 shows a 
representative list of peptides and corresponding source proteins identified from 
RCC190. The specimens differed in their HLA genotypes, in weight and in the 
number of identified ligands. There was no correlation between tumor weight and 
number of identified ligands. Peptide source proteins could be divided into two 
groups. On the one hand, ligands which should be presented by leukocytes were 
found, such as peptides from complement components C3, C4A, C4 binding protein 
alpha, and CD14, and Fc fragment of IgG binding protein. On the other hand, we 
found peptides probably presented by tumor cells from overexpressed TAA, for 
example from vimentin, matrix metalloproteinase 7, eukaryotic translation elongation 
factor 1 alpha 1, and nicotinamide N-methyltransferase. This observation is in 
accordance with immunohistochemistry data (Figure 1) and demonstrates that class 
II positive tumor cells and infiltrating leukocytes were present in analyzed specimens 
and that the eluted peptides were very likely derived from these distinct cell types. 
In order to identify peptides from TAA, we compared ligand source proteins with 
overexpressed genes detected by microarray analysis of tumors [26; 27]. We 
identified a peptide from insulin-like growth factor binding protein 3, IGFBP3166-181, on 
RCC190. In addition, two variants of this peptide, IGFBP3169-181 and IGFBP3169-184, 
were found on TCC108. From the same tumor a peptide from matrix 
metalloproteinase 7, MMP7247-262, could be isolated (Table 2). At the mRNA level, 
MMP7 was overexpressed in 13 and IGFBP3 in 22 of 23 analyzed RCC (data not 
shown) and both have been described to be tumor-associated [28-30]. To test these 
peptides for their immunostimulatory capacity by in vitro T cell priming experiments, 
the shortest variant of the IGFBP3 peptides, IGFBP3169-181, and the MMP7 peptide 
were used. 
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Table 2: HLA-DR peptide sequences. Peptides were isolated from solid tumors (RCC, 
TCC, CCA). Shown are peptide sequences, source tumors and corresponding HLA-DR 
genotypes, source proteins, and Entrez GeneIDs of source proteins. 
RCC211 (B1*07, B1*08, B4) 
Peptide Sequence Gene Symbol Entrez GeneID 
LSALEEYTKKLNTQ APOA1 335 
KIAFSATRTINVPL C1QB 713 
YSIFSYATKRQDNE CRP 1401 
LMHPDALEEPDDQNRI FCGR2B 2213 
NLRFLATTPNSL FN1 2335 
SNTDLVPAPAVRILTPE GDF15 9518 
LASVSTVLTSKYR HBA2 3040 
LVVYPWTQRF HBB 3043 
VVYPWTQRF HBB 3043 
VRFDSDVGEY HLA-DRB1 3123 
INEQWLLTTAKNL HP 3240 
KDSTYSLSSTLTLSK IGKC 3514 
GSEMVVAGKLQDRGPD ITIH4 3700 
GKIVDLVKELDR SERPINA1 5265 
KAVLTIDEKGTEA SERPINA1 5265 
PYFPTTARKL SLC4A4 8671 
GAYKAIPVAQDLN SPP1 6696 
GAYKAIPVAQDLNAPS SPP1 6696 
NGAYKAIPVAQDLNAP SPP1 6696 
NGAYKAIPVAQDLNAPS SPP1 6696 
 
 
RCC190 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
WISKQEYDESGPSIVHRKCF ACTG1 71 
LKKYLYEIARRHP ALB 213 
TLVEVSRNLGKVG ALB 213 
STPTLVEVSRNLGKVG ALB 213 
TPTLVEVSRNLGKVG ALB 213 
TPTLVEVSRNLGKVGSK ALB 213 
VSTPTLVEVSRNLGKVG ALB 213 
STPTLVEVSRNLGKVGS ALB 213 
TPTLVEVSRNLGKVGS ALB 213 
EKSKEQLTPLIKKAGTELVNF APOA2 336 
YPKSLHMYANRLLDHR APOB 338 
DYPKSLHMYANRLLDHR APOB 338 
EPYYKMQTRAGSRE C1R 715 
APPSGGPGFLSIERPDSRPP C4B 721 
APPSGGPGFLSIERPDSRPPR C4B 721 
LTSVSVFVDHHLAPS C4B 721 
GFGPIYNYKDTIVFK C4BPA 722 
FGPIYNYKDTIVFK C4BPA 722 
SPDPSIYAYDNF CALR 811 
EPPVIQNPEYKGEWKPRQIDNPD CALR 811 
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RCC190 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
GVIKVFNDMKVRKS CFL1 1072 
GVIKVFNDMKVRK CFL1 1072 
DGVIKVFNDMKVRK CFL1 1072 
APGYLAITKKVAVPY CPE 1363 
ASVDLKNTGREEFLTA FCGBP 8857 
GNHQFAKYKSFKVADE FCN1 2219 
GVSHFFRELAEEKREG FTL 2512 
VSHFFRELAEEKREG FTL 2512 
TPDAMKAAMALEKK FTL 2512 
FVMGVNHEKYDN GAPD 2597 
TGVFTTMEKAGAHL GAPD 2597 
TGVFTTMEKAGAH GAPD 2597 
STGVFTTMEKAGAH GAPD 2597 
STGVFTTMEKAGAHL GAPD 2597 
ISWYDNEFGYSNRVVDLMAHMASKE GAPD 2597 
GTGASGSFKLNKKAASGEAKPKA HIST1H1C 3006 
GTGASGSFKLNKKAASGEAKPK HIST1H1C 3006 
DVGVYRAVTPQGRPD HLA-DQB1 3119 
DVGEFRAVTELGRPD HLA-DRB1 3123 
HPLHSKIIIIKKGHAK IGFBP3 3486 
DKDLFKAVDAALKK KNG1 3827 
KDKTYSYLNKLPVK NPC2 10577 
ILVIKMGVAAHKKSHEESHKE S100A8 6279 
LILVIKMGVAAHKKSHEESHKE S100A8 6279 
VIKMGVAAHKKSHEESHKE S100A8 6279 
ILVIKMGVAAHKKSHEESH S100A8 6279 
MIEQNTKSPLFMGKVVNPTQK SERPINA1 5265 
LMIDQNTKSPLFMGKVVNPTQK SERPINA1 5265 
AGPHFNPLSRKHGGPK SOD1 6647 
GPHFNPLSRKHGGPK SOD1 6647 
DPQTFYYAVAVVKKDSG TF 7018 
DPQTFYYAVAVVKKDS TF 7018 
 
 
RCC186 (B1*04, B1*11, B3, B4) 
Peptide Sequence Gene Symbol Entrez GeneID 
QEYDESGPSIVHRK ACTG1 71 
FGGPGTASRPSSS VIM 7431 
YASSPGGVYATR VIM 7431 
SLYASSPGGVYATR VIM 7431 
 
 
RCC180 (B1*13, B1*14, B3) 
Peptide Sequence Gene Symbol Entrez GeneID 
AQVIILNHPGQISAG EEF1A1 1915 
VIILNHPGQISAG EEF1A1 1915 
LVVYPWTQRF HBB 3043 
VVYPWTQRF HBB 3043 
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RCC163 (B1*07, B1*13, B3, B4) 
Peptide Sequence Gene Symbol Entrez GeneID 
ATGTIQEDYLREL MRCL3 10627 
FGEKLNGTDPEDVIRNAF MRCL3 10627 
FQVDNNNRLL A2M 2 
INEQWLLTTAKNL HP 3240 
KVNVDEVGGEALGRL HBB 3043 
LVVYPWTQRF HBB 3043 
VNVDEVGGEALGRL HBB 3043 
VVYPWTQRF HBB 3043 
WGKVNVDEVGGEALGRL HBB 3043 
WISKQEYDESGPSIVHRKCF ACTG1 71 
YDNEFGYSNRVVDL GAPD 2597 
 
 
RCC158 (B1*01, B1*16, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
DVVYALKRQGRTLYGFGG HIST1H4A 8359 
IDINEDAEGEAA PAMCI 9182 
VHLTPEEKSAVTALWGKVNVDEVGGEALGRL HBB 3043 
LVVYPWTQRF HBB 3043 
LVVYPWTQRFFES HBB 3043 
VVYPWTQRF HBB 3043 
SPMYSIITPNILR C3 718 
SPMYSIITPNILRL C3 718 
YSIITPNILR C3 718 
VLSPADKTNVKAAWGKVGAHAGEYGAEALERM HBA2 3040 
LASVSTVLTSKYR HBA2 3040 
WVIKTEMGKVL CUBN 8029 
 
 
RCC157 (B1*07, B1*16, B4, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
RVAPEEHPVL ACTB 60 
VEFSSGLKGMSL ATP5A1 498 
ASVDLKNTGREEFLTA FCGBP 8857 
VLSPADKTNVKAAWGKVGAHAGEYGAEALER HBA2 3040 
ASVSTVLTSKYR HBA2 3040 
AAHLPAEFTPAVH HBA2 3040 
VLSPADKTNVKAAWGKVGAHAGEYGAEALERM HBA2 3040 
VLSPADKTNVKA HBA2 3040 
SVSTVLTSKYR HBA2 3040 
EVGGEALGRL HBB 3043 
VHLTPEEKSAVTAL HBB 3043 
VHLTPEEKSAVT HBB 3043 
LVVYPWTQRF HBB 3043 
VHLTPEEKSAVTALWGKVNVDEVGGEALGRL HBB 3043 
KVNVDEVGGEALGRL HBB 3043 
VDEVGGEALGRL HBB 3043 
GKVNVDEVGGEALGRL HBB 3043 
LVVYPWTQR HBB 3043 
VYPWTQRF HBB 3043 
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RCC157 (B1*07, B1*16, B4, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
VDPENFRLLG HBB 3043 
WGKVNVDEVGGEALGRL HBB 3043 
VVYPWTQRF HBB 3043 
VDEVGGEALGRLL HBB 3043 
GKVNVDEVGGEALGRLL HBB 3043 
WGKVNVDEVGGEALGRLL HBB 3043 
VVYPWTQR HBG2 3048 
IKEEHVIIQAE HLA-DRA 3122 
IKEEHVIIQAEF HLA-DRA 3122 
ESRAQLGGPEAAKSDETAAK HSPB1 3315 
FRDGDILGKYVD HSPE1 3336 
VDGEPLGRVSFEL PPIA 5478 
RQDVVRIVGEY PPM2C 54704 
 
 
RCC155 (B1*03, B1*04, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
WISKQEYDESGPSIVHRKCF ACTG1 71 
ISKQEYDESGPSIVHRKCF ACTG1 71 
GPGLIYRQPNCDDPE AHSG 197 
GVDEVTIVNILTNRSNAQ ANXA2 302 
EVTIVNILTNRSN ANXA2 302 
EVTIVNILTNRSNAQ ANXA2 302 
VPYVIVPLKTGLQE C3 718 
DNELQEMSNQGSK CLU 1191 
NELQEMSNQGSK CLU 1191 
WGALATISTLEAVR CREG 8804 
EETVITVDTKAAGKGK FLNA 2316 
ISWYDNEFGYSNRVVDL GAPD 2597 
VHLTPEEKSAVTALWGKVNVDEVGGEALGRL HBB 3043 
LVVYPWTQRF HBB 3043 
VVYPWTQRF HBB 3043 
GSHSMRYFDTAMSRPG HLA-B 3106 
NTILPDARDPAFK LAMP1 3916 
VADKIQLINNMLDK PGK1 5230 
VPSIKFCLDNGAK PGK1 5230 
LDFLKAVDTNRASVG PLXDC2 84898 
KAVLTIDEKGTEAA SERPINA1 5265 
KAVLTIDEKGTEA SERPINA1 5265 
APEEIIMDRPFLFVVR SERPINE1 5054 
GVVHVITNVLQPPA TGFBI 7045 
GVVHVITNVLQPP TGFBI 7045 
TTTQLYTDRTEKLRPE TGFBI 7045 
NGVVHVITNVLQPP TGFBI 7045 
TNGVVHVITNVLQPPA TGFBI 7045 
TNGVVHVITNVLQPP TGFBI 7045 
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RCC149 (B1*01, B1*13, B3) 
Peptide Sequence Gene Symbol Entrez GeneID 
SGTLVLLQGARGFA CD14 929 
VSGTLVLLQGARGFA CD14 929 
VSGTLVLLQGARG CD14 929 
LVVYPWTQRF HBB 3043 
APSAILPLPGQSVER ITIH4 3700 
ASSLVIIWGIL KIAA0877 23333 
SPERPFLAILGGAKVADK PGK1 5230 
PAILSEASAPIPH SDCBP 6386 
FGGPGTASRPSSS VIM 7431 
 
 
RCC132 (B1*04, B1*08, B4) 
Peptide Sequence Gene Symbol Entrez GeneID 
TPTLVEVSRNLGK ALB 213 
FPKAEFAEVSKLVTD ALB 213 
PKAEFAEVSKLVTD ALB 213 
DVPKWISIMTERSVPH ANXA2 302 
IQHFQAMVKALEKE APLP2 334 
IQHFQAMVKALEKEA APLP2 334 
TFQMKKNAEELK APOA4 337 
GLTFQMKKNAEELK APOA4 337 
EGLTFQMKKNAEELKA APOA4 337 
EGLTFQMKKNAEELK APOA4 337 
GLTFQMKKNAEELKA APOA4 337 
EPGTWKISARFSDG C4B 432395 
ILCVTKAREGSE CASP14 23581 
IKGKINSITVDNCKK CAP1 10487 
NTGVISVVTTGLDR CDH1 999 
VPRYLPRPANPDE CDH1 999 
ETGWLLLNKPLDR CDH3 1001 
DPSPSPVLGYKIVYKPVG COL12A1 1303 
RPKDYEVDATLKSLNN COL1A2 1278 
LPGETLTYVWKIPER CP 1356 
DNGFFKILRGQDH CTSB 1508 
LPQSIVYKYMSIRSDRSVPS EFEMP1 2202 
SGKYDLDFKSPDDPSR ENO1 2023 
IPGHLNSYTIKGLKPG FN1 2335 
LNSYTIKGLKPG FN1 2335 
LTGYRVRVTPKEKTGP FN1 2335 
TGYRVRVTPKEKTGPM FN1 2335 
ITGYIIKYEKPGSPP FN1 2335 
LVVYPWTQRF HBB 3043 
VVYPWTQRF HBB 3043 
FVRFDSDAASPR HLA-C 3107 
KDILEEKRAVPDR HLA-DPB1 3115 
DILEEKRAVPDR HLA-DPB1 3115 
YVGKKQLVEIEK HPR 3250 
APTLTLYVGKKQLVEIEK HPR 3250 
SYAYSLKNQIGDKEK HSPA5 3309 
YAYSLKNQIGDKEK HSPA5 3309 
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RCC132 (B1*04, B1*08, B4) 
Peptide Sequence Gene Symbol Entrez GeneID 
AYSLKNQIGDK HSPA5 3309 
ESYAYSLKNQIGDKEK HSPA5 3309 
GIFEVKSTAGDTH HSPA8 3312 
KHKVYACEVTHQG IGKC 3514 
GSEMVVAGKLQDRGPDV ITIH4 3700 
KGSEMVVAGKLQDRGPD ITIH4 3700 
MVVAGKLQDRGPD ITIH4 3700 
KGSEMVVAGKLQDRGPDV ITIH4 3700 
FKGSEMVVAGKLQDRGPDV ITIH4 3700 
GSEMVVAGKLQDRGPD ITIH4 3700 
QGSYVPLLRDTDSS LISCH7 51599 
DAIWNLLRQAQEK LTF 4057 
APYKLRPVAAEVYG LTF 4057 
GLAPYKLRPVAAEVYG LTF 4057 
KPPQYIAVHVVPDQ MIF 4282 
KDKTYSYLNKLPVK NPC2 10577 
QRESYELKVVAADRGSPS PCDH1 5097 
EPHRHSIFTPETNPRAG PLG 5340 
LDFLKAVDTNRAS PLXDC2 84898 
DPGVLDRMMKKLDTNSD S100A11 6282 
FHQYSVKLGHPDT S100A9 6280 
DLQNFLKKENKNEKVIE S100A9 6280 
DLQNFLKKENKNEK S100A9 6280 
DLQNFLKKENKNEKV S100A9 6280 
DLQNFLKKENKNEKVI S100A9 6280 
HQYSVKLGHPDT S100A9 6280 
TQGKIVDLVKELDRD SERPINA1 5265 
TQGKIVDLVKELDR SERPINA1 5265 
GTQGKIVDLVKELDR SERPINA1 5265 
TQGKIVDLVKELDRDT SERPINA1 5265 
QGKIVDLVKELDRDT SERPINA1 5265 
IVDLVKELDR SERPINA1 5265 
IVDLVKELDRDT SERPINA1 5265 
GTQGKIVDLVKELDRDT SERPINA1 5265 
QGKIVDLVKELDR SERPINA1 5265 
EAIYDICRRNLDIERP TUBA6 84790 
ELDEKAVRPG VTN 7448 
VVSSIEQKTEGAEKK YWHAZ 7534 
VSSIEQKTEGAEKK YWHAZ 7534 
 
 
 
TCC108 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
GNRIAQWQSFQLEGG A2M 2 
KPKDPTFIPAPIQAKTSPV AGT 183 
STPTLVEVSRNLGKVG ALB 213 
TPTLVEVSRNLGKVG ALB 213 
PTLVEVSRNLGKVG ALB 213 
VSTPTLVEVSRNLGKVG ALB 213 
STPTLVEVSRNLGKVGSK ALB 213 
Results and Discussion, Part 2  95
TCC108 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
IPEDSIFTMADRGECVPG AMBP 259 
TPPSAYGSVKAYTNFDAER ANXA2 302 
TPPSAYGSVKAYTNFDAERD ANXA2 302 
TPPSAYGSVKAYTNFDAERDA ANXA2 302 
AYGSVKAYTNFDAER ANXA2 302 
GIAEFWINGTPLVK APCS 325 
GIAEFWINGTPLVKKG APCS 325 
YPKSLHMYANRLLDHR APOB 338 
YPKSLHMYANRLLD APOB 338 
EPYYKMQTRAGSR C1R 715 
EPYYKMQTRAGSRE C1R 715 
AGYALAQMGRLKGPLL C3 718 
GGPGFLSIERPDSRPP C4B 721 
APPSGGPGFLSIERPDSRPPR C4B 432395 
APPSGGPGFLSIERPDSRPP C4B 721 
FGPIYNYKDTIVFK C4BPA 722 
GPIYNYKDTIVFK C4BPA 722 
GFGPIYNYKDTIVFK C4BPA 722 
DHIGIISFPDFKIPSNPR C5 727 
VPAQLLVGALRVLAYSR CD14 929 
VSDGVIKVFNDMKVRKS CFL1 1072 
VSDGVIKVFNDMKVRK CFL1 1072 
SDGVIKVFNDMKVRK CFL1 1072 
DGVIKVFNDMKVRK CFL1 1072 
GVIKVFNDMKVRKS CFL1 1072 
SDGVIKVFNDMKVRKSSTPE CFL1 1072 
GVIKVFNDMKVRK CFL1 1072 
TPDTIRRFQSVPAQPG CLTC 1213 
AGLLSTYRAFLSSH COL15A1 1306 
AAGLLSTYRAFLSSH COL15A1 1306 
APGYLAITKKVAVPY CPE 1363 
SAPGYLAITKKVAVPY CPE 1363 
GAFSVYSDFLLYK CTSB 1508 
GPVEGAFSVYSDFLLYKS CTSB 1508 
GPVEGAFSVYSDFLLYK CTSB 1508 
VPDDRDFEPSLGPVCPFR DCN 1634 
GPLGITGFLGPLFFL est - 
SDSIQWFHNGNLIPT FCGR2B 2213 
GATYNIIVEALKDQ FN1 2335 
TPDAMKAAMALEKK FTL 2512 
TGVFTTMEKAGAHL GAPD 2597 
APMFVMGVNHEKYDN GAPD 2597 
STGVFTTMEKAGAHL GAPD 2597 
GVFTTMEKAGAH GAPD 2597 
STGVFTTMEKAGAH GAPD 2597 
DAPMFVMGVNHEKYDN GAPD 2597 
GKHVLFVNVAAYCGLAA GPX6 257202 
GKPMIIYKGGTSR GSN 2934 
VGVYRAVTPQGRPD HLA-DQB1 3119 
GVYRAVTPQGRPD HLA-DQB1 3119 
DVGVYRAVTPQGRPD HLA-DQB1 3119 
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TCC108 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
RLEEFGRFASFEAQGAL HLA-DRA 3122 
LEEFGRFASFEAQG HLA-DRA1 3122 
FQTLVMLETVPRSG HLA-DRB1 3123 
DVGEYRAVTELGRPD HLA-DRB1 3123 
DVGEFRAVTELGRPD HLA-DRB1 3123 
TAPKLLIYSNNQRPS Ig lambda - 
FPPSSEELQANKATLVCL Ig lambda - 
HSKIIIIKKGHAK IGFBP3 3486 
HSKIIIIKKGHAKDSQ IGFBP3 3486 
LPGTAPKLLIYSNNQRPSG Ig lambda - 
GPEDNVVIIYLSRAGNPE ISLR 3671 
AISDYVFNTASLVYHEE LBP 3929 
ISDYVFNTASLVYHEE LBP 3929 
DDIIVNWVNETLRE LCP1 3936 
NDDIIVNWVNETLRE LCP1 3936 
SNPVDILTYVAWKISGFPK LDHA 3939 
NPVDILTYVAWKLSGFPK LDHAL6A 160287 
TPQNFLAVLRGDAEA LGMN 5641 
LDLSFNQIARLPSGLPV LUM 4060 
DLSFNQIARLPSGLPV LUM 4060 
DLSFNQIARLPSG LUM 4060 
SQDDIKGIQKLYGKRS MMP7 4316 
QEKNIMLYKGSGLWSR MRC1 4360 
DGRAYTAISHIPQPA NID2 22795 
EGLFSLVARKLSRP NNMT 4837 
ITGKWFYIASAFRNEE ORM1 5004 
LGEFYEALDCLRIPK ORM1 5004 
HGNQIATNGVVHVIDR POSTN 10631 
AHGRINPYMSSPCH RPL17 6139 
EMINPYRNLPLA SLC7A5 8140 
GPHFNPLSRKHGGPK SOD1 6647 
AGPHFNPLSRKHGGPK SOD1 6647 
GNAIFTFPNTPVK SQRDL 58472 
TPLPLIKPYSGPRLPP TAF9 6880 
EDPQTFYYAVAVVKKDSG TF 7018 
ERPTYTNLNRLISQ TUBA4 80086 
 
 
 
CCA156 (B1*01, B1*03, B3) 
Peptide Sequence Gene Symbol Entrez GeneID 
APSAILPLPGQSVER ITIH4 3700 
LVAYYTLIGASGQR C3 718 
SPMYSIITPNILR C3 718 
SPMYSIITPNILRL C3 718 
YSIITPNILR C3 718 
YSIITPNILRL C3 718 
VSGTLVLLQGARGFA CD14 929 
DTSYVSLKAPLTK CRP 1401 
IEKFEKEAAEMGKG EEF1A1 1915 
KNGFVVLKGRPCK EIF5A 1984 
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CCA156 (B1*01, B1*03, B3) 
Peptide Sequence Gene Symbol Entrez GeneID 
ASVDLKNTGREEF FCGBP 8857 
ASVDLKNTGREEFL FCGBP 8857 
ASVDLKNTGREEFLTAF FCGBP 8857 
VDLKNTGREEF FCGBP 8857 
VDLKNTGREEFL FCGBP 8857 
EETVITVDTKAAGKGK FLNA 2316 
ETVITVDTKAAGKGK FLNA 2316 
TGDAYVILKTVQLRNG GSN 2934 
LVVYPWTQRF HBB 3043 
TAEILELAGNAARDNK HIST3H2A 92815 
MFYVDLDKKETVWH HLA-DPA1 3113 
SPERPFLAILGGAKVADK PGK1 5230 
DTKVYTVDLGRTVT PIGR 5284 
WAAEVISDARENIQR SAA1 6288 
KAVLTIDEKGTEA SERPINA1 5265 
NTDPYQLMNAVNTLDR SULF2 55959 
 
 
CCA164 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
TPTLVEVSRNLGKVG ALB 213 
STPTLVEVSRNLGKVG ALB 213 
TPTLVEVSRNLGKVGSK ALB 213 
TPPSAYGSVKAYTNFDAERDA ANXA2 302 
SKEQLTPLIKKAGTE APOA2 336 
GLADASLLKKV ATXN10 5814 
KMDPIISRV BTG2 7832 
EPYYKMQTRAGSRE C1R 715 
HEPYYKMQTRAGSRE C1R 715 
APPSGGPGFLSIERPDSRPP C4A 720 
GGPGFLSIERPDSRPP C4A 720 
GVIKVFNDMKVRK CFL1 1072 
DGVIKVFNDMKVRK CFL1 1072 
FLFLDRTYV CUL4B 8450 
ASVDLKNTGREEFLT FCGBP 8857 
VDLKNTGREEFLTA FCGBP 8857 
ASVDLKNTGREEFLTAF FCGBP 8857 
NTGREEFLTA FCGBP 8857 
ASVDLKNTGREEFL FCGBP 8857 
ASVDLKNTGREEF FCGBP 8857 
ASVDLKNTGREEFLTAFLQN FCGBP 8857 
YSKAYPRLLISSL FCGBP 8857 
ASVDLKNTGREEFLTA FCGBP 8857 
FLDPDRHFL FLJ46072 286077 
NPAEFVVNTSNAGAG FLNA 2316 
TGVFTTMEKAGAHL GAPD 2597 
STGVFTTMEKAGAHL GAPDH 2597 
TGVFTTMEKAGAH GAPDH 2597 
GVFTTMEKAGAHL GAPDH 2597 
DVGVYRAVTPQGRPD HLA-DQB1 3119 
LEEFGRFASFEAQG HLA-DRA 3122 
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CCA164 (B1*11, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
DVGEFRAVTELGRPD HLA-DRB1 3123 
ILLDIKTRL KRT20 54474 
DLSFNQIARLPSG LUM 4060 
NEEEIRANVAVVSGAP SDCBP 6386 
AGPHFNPLSRKHGGPK SOD1 6647 
DPQTFYYAVAVVKKDSG TF 7018 
GKKEYLIAGKAEGDG TIMP2 7077 
FLYDDNQRV TOP2A 7153 
 
 
CCA165 (B1*13, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
LKKYLYEIARRHP ALB 213 
YPKSLHMYANRLLDHR APOB 338 
TPKIQVYSRHPAENGK B2M 567 
TPKIQVYSRHPAEN B2M 567 
RTPKIQVYSRHPAENGK B2M 567 
RTPKIQVYSRHPAENG B2M 567 
RTPKIQVYSRHPAEN B2M 567 
GPGEQQKRKIVLDPSGSMN BF 629 
LPKPPKPVSKMRMATPLLMQ CD74 972 
DGVIKVFNDMKVRK CFL1 1072 
GVIKVFNDMKVRK CFL1 1072 
DGVIKVFNDMKVR CFL1 1072 
AQVIILNHPGQISA EEF1A1 1915 
AQVIILNHPGQISAG EEF1A1 1915 
TAQVIILNHPGQIS EEF1A1 1915 
TAQVIILNHPGQISAG EEF1A1 1915 
VIILNHPGQISAG EEF1A1 1915 
VIILNHPGQIS EEF1A1 1915 
SVDLKNTGREEFLTA FCGBP 8857 
YSKAYPRLLISSL FCGBP 8857 
NTGREEFLTA FCGBP 8857 
VDLKNTGREEF FCGBP 8857 
ASVDLKNTGREEFLTAFLQN FCGBP 8857 
ASVDLKNTGREEFLTAF FCGBP 8857 
NTGREEFLTAF FCGBP 8857 
KNTGREEFLTA FCGBP 8857 
NTGREEFLTAFLQN FCGBP 8857 
ASVDLKNTGREE FCGBP 8857 
SVDLKNTGREEF FCGBP 8857 
DLKNTGREEFLTA FCGBP 8857 
LKNTGREEFLTA FCGBP 8857 
ASVDLKNTGREEF FCGBP 8857 
ASVDLKNTGREEFL FCGBP 8857 
ASVDLKNTGREEFLTA FCGBP 8857 
VDLKNTGREEFLTA FCGBP 8857 
FVMGVNHEKYDN GAPD 2597 
DAPMFVMGVNHEKYDN GAPD 2597 
SDVGEFRAVTELGRPD HLA-DPB1 3115 
DVGEFRAVTELGRPA HLA-DPB1 3115 
Results and Discussion, Part 2  99
CCA165 (B1*13, B1*15, B3, B5) 
Peptide Sequence Gene Symbol Entrez GeneID 
DVGVYRAVTPQGRPD HLA-DQB1 3119 
SDVGVYRAVTPQGRPD HLA-DQB1 3119 
DVGVYRAVTPQGRPV HLA-DQB1 3119 
LEEFGRFASFEAQG HLA-DRA 3122 
VPPEVTVLTNSPVELREP HLA-DRA 3122 
VPPEVTVLTNSPVELREPN HLA-DRA 3122 
DVGEFRAVTELGRPDA HLA-DRB1 3123 
DVGEFRAVTELGRPD HLA-DRB1 3123 
DVGEYRAVTELGRPV HLA-DRB1 3123 
YGGGNYGPGGSGGSGGYGGRS HNRPA2B1 3181 
VEIIANDQGNRITPS HSPA5 3309 
LPREKYLTWASRQEPS IGHA2 3494 
HGNQIATNGVVHVIDR POSTN 10631 
IYRNTGTEAPDY SELENBP1 8991 
IPLEIRFLHNPDAAQG SELENBP1 8991 
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Table 3: HLA-DR ligands isolated from RCC190. 
Shown are the core sequences of HLA-DR ligands isolated from RCC190 (HLA-DRB1*11, 
DRB1*15, DRB3, DRB5).  
Gene 
Symbol 
Entrez 
GeneID 
Peptide Sequence Gene Titel 
ACTG1 71 WISKQEYDESGPSIVHRKCF actin, gamma 1 propeptide 
ALB 213 LKKYLYEIARRHP albumin precursor 
ALB 213 TLVEVSRNLGKVG albumin precursor 
ALB 213 TPTLVEVSRNLGKVGS albumin precursor 
APOA2 336 EKSKEQLTPLIKKAGTELVNF apolipoprotein A-II precursor 
APOB 338 YPKSLHMYANRLLDHR apolipoprotein B precursor 
C1R 715 EPYYKMQTRAGSRE complement component 1, r 
subcomponent 
C4B 721 APPSGGPGFLSIERPDSRPP complement component 4B 
proprotein 
C4BPA 722 FGPIYNYKDTIVFK complement component 4 binding 
protein, alpha 
CALR 811 SPDPSIYAYDNF calreticulin precursor 
CALR 811 EPPVIQNPEYKGEWKPRQIDNPD calreticulin precursor 
CFL1 1072 GVIKVFNDMKVRK cofilin 1 (non-muscle) 
CPE 1363 APGYLAITKKVAVPY carboxypeptidase E precursor 
FCGBP 8857 ASVDLKNTGREEFLTA Fc fragment of IgG binding 
protein 
FCN1 2219 GNHQFAKYKSFKVADE ficolin 1 precursor 
FTL 2512 VSHFFRELAEEKREG ferritin, light polypeptide 
FTL 2512 TPDAMKAAMALEKK ferritin, light polypeptide 
GAPD 2597 FVMGVNHEKYDN glyceraldehyde-3-phosphate 
dehydrogenase 
GAPD 2597 TGVFTTMEKAGAH glyceraldehyde-3-phosphate 
dehydrogenase 
GAPD 2597 ISWYDNEFGYSNRVVDLMAHMASKE glyceraldehyde-3-phosphate 
dehydrogenase 
HIST1H1C 3006 GTGASGSFKLNKKAASGEAKPK H1 histone family, member 2 
HLA-DQB1 3119 DVGVYRAVTPQGRPD major histocompatibility complex, 
class II, DQ beta 1 precursor 
HLA-DRB1 3123 DVGEFRAVTELGRPD major histocompatibility complex, 
class II, DR beta 1 precursor 
IGFBP3 3486 HPLHSKIIIIKKGHAK insulin-like growth factor binding 
Results and Discussion, Part 2  101
protein 3 
KNG1 3827 DKDLFKAVDAALKK kininogen 1 
NPC2 10577 KDKTYSYLNKLPVK Niemann-Pick disease, type C2 
precursor 
S100A8 6279 VIKMGVAAHKKSHEESHKE S100 calcium-binding protein A8 
SERPINA1 5265 MIEQNTKSPLFMGKVVNPTQK serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 
member 1 
SOD1 6647 GPHFNPLSRKHGGPK superoxide dismutase 1, soluble 
TF 7018 DPQTFYYAVAVVKKDS transferrin 
 
 
Antigen-specific CD4+ T cells against IGFBP3169-181 and MMP7247-262 
The peptides IGFBP3169-181 and MMP7247-262 were analyzed with respect to their 
binding characteristics by the SYFPEITHI class II epitope prediction algorithm 
(www.syfpeithi.de). The HLA-DR genotypes of the source tumors were HLA-DRB1*11 
and DRB1*15 (Table 2) in both cases. According to the epitope predictions for 
DRB1*1101 and DRB1*1501, both peptides received a high binding score for HLA-
DRB1*11 (data not shown). To generate antigen-specific CD4+ T cells and to test the 
peptides for promiscuous binding, PBMCs of 4 healthy donors with different HLA-DR 
alleles (Figure 2), one of them carrying DRB1*1101, were stimulated using peptide-
pulsed autologous DCs. In addition, the peptide CCND1198-212, a known T cell epitope 
[31], was used as positive control. As a read-out system for the generation of 
antigen-specific CD4+ T cells, IFNγ levels were assessed by flow cytometry. T cells 
were analyzed after the third and fourth weekly stimulation by intracellular IFNγ 
staining plus CD4-FITC and CD8-PerCP staining to determine the percentage of 
IFNγ-producing cells in specific T-cell subpopulations. In all experiments, stimulations 
with irrelevant peptide and without peptide were performed as negative controls. IFNγ 
response was considered as positive if the percentage of IFNγ producing CD4+ T 
cells was more than two-fold higher compared with negative controls [32]. 
In three of four donors we were able to generate specific CD4+ T cells for both 
peptides (Figure 2). T cell responses could not be observed in donor 4 after any 
stimulation. In donor 1, 0.05% to 0.1% (Figure 3) IFNγ producing CD4+ T cells were 
detected in all seven stimulation attempts after the third stimulation with peptide 
IGFBP3169-181. These T cells could be expanded in most cases by an additional round 
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of stimulation to 0.09% to 0.13%. IFNγ-producing CD4+ T cells specific for the 
peptide IGFBP3169-181 were also observed in donor 2 and donor 3, with maximal 
frequencies of 0.05% and 0.07% IFNγ producing CD4+ T cells. 
Donors 1, 2, and 3 also showed CD4+ T cells reactive to peptide MMP7247-262. The 
highest frequencies of IFNγ producing CD4+ T cells specific for the MMP7 peptide 
were found in donors 1 and 2, respectively. Donors 1, 2, and 3 showed IFNγ 
responses to peptide CCND1198-212, which has already been described as an MHC 
class II-restricted T cell epitope [33]. 
Thus, peptides from IGFBP3, MMP7, and CCND1 are promiscuous HLA class II 
binders that are able to elicit CD4+ T cell responses in three out of four healthy 
donors carrying different HLA alleles. If the HLA alleles of the two tumor patients from 
which the IGFBP3 and MMP7 peptides were derived are compared to those of the 
four healthy donors, it seems very likely that the peptides are presented by HLA-
DRB1*01, HLA-DRB1*04 and HLA-DRB1*11. All three allotypes have a glycine 
residue at position 86 and an aspartic acid residue at position 57 of their β chains 
(see www.anthonynolan.com/HIG). Therefore, they have very similar binding 
characteristics for their binding pockets P1 and P9 [34]. For peptide CCND1198-212, a 
T cell epitope known to be presented by HLA-DRB1*0401 and HLA-DRB1*0408 [35], 
the same holds true. Donor 4 carries HLA-DRB1*0318 and HLA-DRB1*1401, alleles 
with peptide motifs that probably differ from those described above. This could 
explain why it was not possible to elicit T cell responses against the two peptides 
using cells from this donor. 
The identification of helper T cell epitopes of TAA remains an important task in anti-
tumor immunotherapy. Until now, different strategies for the identification of class II 
peptides from TAA have been carried out, ranging from the incubation of APCs with 
the antigen of interest in order to be taken up and processed [36] to various 
transfection strategies with fusion proteins [37]. All these methods are very time-
consuming and it often remains unclear if the identified ligands are presented in vivo. 
We could show that it is possible to isolate class II ligands from dissected solid 
tumors, thus identifying the peptides which are presented by tumors and surrounding 
tissue in vivo. Among the source proteins several housekeeping and immunorelevant 
proteins were present. However, peptides from TAA could also be detected, leading 
to a straightforward approach for the identification of in vivo relevant class II ligands 
of TAA. 
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We identified three ligands accounting for one core sequence from IGFBP3 and one 
ligand from MMP7. We found these proteins to be overexpressed in renal cell 
carcinomas, in addition, they have been described as tumor-associated [38-40]. 
These peptides bound promiscuously to HLA class II molecules and were able to 
activate CD4+ T cells from different healthy donors. Thus, our approach will be helpful 
in the identification of new class II peptide candidates from TAA for use in clinical 
vaccination protocols. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: CD4+ T cells specific for IGFBP3169-181, MMP7247-262.and CCND1198-212. Shown are 
representative dot blots of intracellular IFNγ staining against CD4-FITC. 
 
 
 
Results and Discussion, Part 2  104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic illustration of antigen-specific IFNγ producing CD4+ T cells detected in 
each donor and for each peptide.  
Shown is the percentage of IFNγ producing CD4+ T cells for each donor and peptide used for 
stimulation. Cells were incubated in 96-well plates – 7 wells per donor and per peptide. Boxed are 
values considered as positive: percentage of IFNγ producing CD4+ T cells was more than two-fold 
higher compared with negative control without peptide. Percentages of IFNγ producing CD4+ T cells 
detected after stimulation with irrelevant peptide correlated with values after stimulation without 
peptide, with the exception of Donor 1 after the 3rd stimulation with IGFBP3169-181. However, this effect 
was not seen anymore after the 4th stimulation. 
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Non-CD4 responses 
Interestingly, IFNγ-producing CD8+ T cells were detected in two donors after 
stimulations with MHC class II peptides, in particular in donor 3, but also to a lesser 
extent in donor 1 (Figure 4). These observations suggest the presence of CD8 T cell 
responses directed against shorter class I epitopes included in the long class II 
peptides, probably after in vitro processing. MHC class I predictions were performed 
using the program SYFPEITHI [41]. Potential CD8 T cell epitopes are listed in Table 
4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. CD4+ and CD8+ T cells specific for IGFBP3, CCND1 and, MMP7. Shown are 
representative dot blots (one of seven) of intracellular IFNγ staining against CD4-FITC and CD8-
PerCP. Non-CD4 IFNγ-reponses were gated and are visualized in red. IFNγ-responses of CD4+ T 
cells are highlighted in green. 
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Table 3. Non-CD4 reactions to 15-20mer peptides and potential class I epitopes. 
Peptide sequence Protein/position (potential) MHC class I 
restriction 
score
 IGFBP3  
HSKIIIIKKGHAKDSQ 
          IIIKKGHAK 
          IIIKKGHAK 
         IIIIKKGHA 
 
 
 
 
 
A*0301 
A*1101 
A*0201 
28
19
17
 CCND1  
NPPSMVAAGSVVAAV 
             VAAGSVVAAV 
                AAGSVVAAV 
                AAGSVVAAV 
   PPSMVAAGSV 
       SMVAAGSVV 
                AAGSVVAAV 
                  AGSVVAAV 
  
A*0201 
A*0201 
B*5101 
B*0702 
A*0201 
B*0702 
B*5101 
26
23
22
20
20
19
17
 MMP7  
SQDDIKGIQKLYGKRS 
SQDDIKGIQKLY 
  QDDIKGIQKLY 
        DIKGIQKL 
        DIKGIQKLY 
  
A*0101 
A*0101 
B*0801 
A*2601 
29
27
24
24
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3.2 CD4+ T cells specific for a peptide derived from the tumor 
antigen survivin 
 
Introduction 
 
BIRC5, also known as survivin is a unique member of the inhibitor of apoptosis (IAP) 
protein family. In contrast to other IAPs, survivin is undetectable in normal adult 
tissues, yet it is abundantly expressed in fetal tissue and in a variety of human tumors 
including lung, colon, breast, prostate, pancreatic, and gastric carcinomas as well as 
in high-grade lymphomas and neuroblastomas [42-45]. Survivin is cell cycle 
regulated and involved in both the control of programmed cell death (apoptosis) and 
the regulation of cell division [46; 47]. As survivin is highly expressed in cancer 
tissues it may be a new target for tumor therapy such as peptide-based 
immunotherapy. For the indentification of MHC class II ligands from survivin for use 
in peptide-based immunotherapy, we predicted a 15mer peptide of the protein – 
TLGEFLKLDRERAKN, survivin97-111. The predicted peptide bound promiscuously to 
HLA-DR molecules as detected by IFNγ-producing CD4+ T cells after in vitro 
stimulation. The identified peptide will be useful as candidate peptide for vaccination 
studies for tumor immunotherapy.  
 
 
Material and Methods 
 
Peptide 
Peptide (TLGEFLKLDRERAKN, survivin97-111) was predicted according to HLA-DR 
peptide motifs [http://www.syfpeithi.de] and synthesized by standard Fmoc chemistry 
using an Economy Peptide Synthesizer EPS 221 (ABIMED, Langen, Germany).  
 
Maturation of DCs 
All steps have already been described in chapter 3.1, part Material and Methods. 
 
Generation of antigen-specific CD4+ T cells 
See chapter 3.1, Material and Methods. 
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Intracellular IFNγ staining 
See chapter 3.1, Material and Methods. 
 
 
Results and Discussion 
 
As can be seen in Figure 1, IFNγ-producing CD4+ T cells were detected after 
stimulation with survivin97-111 in three of four donors, whereby all donors carried 
different HLA alleles (Table 1). Thus, the peptide from survivin is a promicuous binder 
being able to activate CD4+ T cells from healthy donors. After the fourth round of 
stimulation only donor 1 showed CD4+ activated T cells, maybe due to a suboptimal 
stimulation protocol. Hence, it was tested if fresh autologous PBMCs used for the 
fourth restimulation lead to a longer survival of the T cells stimulated. The use of 
fresh isolated PBMCs as antigen presenting cells extend T cell survival (data not 
shown).  
The verification of novel MHC class II ligands from tumor-associated antigens, which 
were predicted by epitope prediction programs, is possible with in vitro stimulation 
protocols using peptide loaded DCs as antigen-presenting cells. The identified new 
MHC class II peptide may be useful in already established clinical vaccination 
protocols.  
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Figure 1. CD4+ T cells specific for survivin97-111. Seven wells per donor were used for stimulation 
with survivin peptide. Shown are representative dot plots (one of seven) of intracellular IFNγ staining 
against CD4-FITC after the third and the fourth stimulation. 
 
 
Table 1. HLA typings of donors tested 
 MHC class II
Donor 1 DRB1*0701 DRB1*0101
Donor 2 DRB1*0101 DRB1*0804
Donor 3 DRB1*0408 DRB1*1101 
Donor 4 DRB1*0318 DRB1*1401
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3.3 CD8 T cell responses to VEGF (vascular endothelial growth 
factor) 
 
Introduction 
 
VEGF is a potent and specific mitogen for vascular endothelial cells that is capable of 
stimulating angiogenesis during embryonic development but also during tumor 
formation. Moreover, VEGF is a key regulator of the process of angiogenesis, which 
makes it attractive as therapeutic target. Several clinical studies have demonstrated 
that cancer vaccines designed to target epitopes which are derived from tumor-
associated antigens and recognized by cytotoxic T cells are able to raise 
immunological and clinical responses, e.g. in renal cell carcinoma (RCC), melanoma, 
prostate and breast cancer. However, these immunotherapeutical approaches are 
restricted by the limited number of known tumor antigens and epitopes, and HLA 
restrictions. Aim of this study was the investigation of immunogenicity of peptide 
SRFGGAVVR (VEGF-114 to -106) as a T-cell epitope by generation of specific CD8+ T 
cells using in vitro priming with artificial antigen presenting cells.  
 
 
Materials and Methods 
 
Donors 
HLA-B*2705 positive buffy coats were obtained from healthy blood bank donors. 
PBMCs were isolated using standard gradient separation (Lymphocyte Separation 
Medium, PAA Laboratories, Pasching, Austria). 
 
Peptide, refolding, fluorescent tetramers and MHC coated microspheres 
Peptides for MHC refoldings were synthesized using standard Fmoc chemistry. 
Peptides were SRFGGAVVR (VEGF-114 to -106) and NLVPMVATV (HCMV pp65495-503).  
Biotinylated recombinant HLA-B*2705 or HLA-A*0201 molecules were produced as 
previously described [48; 49]. Monomers were fluorescence labeled by coincubating 
biotinylated HLA monomers with streptavidin-PE or streptavidin-APC (Molecular 
Probes, Leiden, The Netherlands) at a 4:1 molar ratio.  
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Microspheres were 5.60 µm diameter streptavidin coated polystyrene particles with a 
binding capacity of 0.064 µg biotin-FITC/mg microspheres (Bangs Laboratories, 
Fishers, Illinois, USA). Microspheres were washed and resuspended at 2 x 106/well  
in PBE [PBS (BioWhittaker/Cambrex Bio Science, Verviers, Belgium) supplemented 
with 0.5% protease-free BSA and 2 mM sodium EDTA (both Sigma-Aldrich, 
Taufkirchen, Germany)] containing biotinylated MHC in two different densities (high 
density (HD): 20 nM; low density (LD): 200 pM) and costimulatory antibodies anti 
human CD28 Ab 9.3 (5 nM) [50] and anti 4-1BBL Ab (15 nM (kindly provided by B.S. 
Kwon, Korea). Suspension was incubated by room temperature for 30 min while 
agitating. Coated beads were washed three times, resuspended in PBE and stored 
for up to 4 weeks at 4°C.  
 
Antigen-specific in vitro stimulation of human CD8+ T cells 
CD8 T cells were magnetically enriched by negative depletion of PBMCs using 
biotinylated anti-CD8 Ab (5 µg/ml) and streptavidin-coated MACS beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany).  
In vitro stimulations were performed in 96-well plates with 1 x 106 sorted CD8+ cells 
plus 2 x 105 coated beads per well in 200 µl T cell medium consisting of RPMI 1640 
containing HEPES and L-glutamine (Gibco, Paisley, UK) supplemented with 10% 
heat-inactivated human serum (PAA, Cölbe, Germany), 50 U/ml penicillin, 50 µg/ml 
streptomycin and 20 µg/ml gentamicin (all BioWhittaker, Verviers, Belgium). 5 ng/ml 
human IL-12 p70 (R&D Systems, Wiesbaden, Germany) was added with beads. Per 
donor, 30 wells with high density loaded microspheres and 30 well with low density 
loaded beads were performed. After 3-4 days coincubation at 37°C, fresh medium 
and 80 U/ml human IL-2 (Chiron, Ratingen, Germany) was added and cells were 
further incubated at 37°C for 3-4 days. Stimulation was repeated twice before 
analysing cells by flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, 
Germany).  
 
Tetrameric analysis 
Cells were washed in PBEA (PBS containing 0.5% protease-free BSA, 2 mM sodium 
EDTA (both Sigma-Aldrich, Taufkirchen, Germany) and 0.01% sodium azide (Merck, 
Darmstadt, Germany) and stained with CD8-PerCP clone SK1 antibody (Becton 
Dickinson, Heidelberg, Germany) in the same buffer for 20 min at 4°C. 100 µg/ml 
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unlabeled streptavidine (Sigma-Aldrich, Taufkirchen, Germany) was included in same 
incubation period. Cells were washed in PFEA ((PBS containing 2% FCS (PAN 
Biotech, Aidenbach, Germany), 2 mM sodium EDTA (Sigma-Aldrich) and 0.01% 
sodium azide (Merck)) and tetramer stained at 4°C for 30 min in PFEA. Fluorescent 
MHC tetramers were always used at concentrations of 5 µg/ml. After washing, 
stained cells were resuspended in 1% paraformaldehyd (Merck) in PFEA. Cells were 
analysed on a four-colour FACSCalibur cytometer (Becton Dickinson). 
 
 
Results and Discussion 
 
For the generation of VEGF-114 to -106 specific cytotoxic T cells, enriched CD8+ T cells 
were stimulated for three 7-9 day rounds in the presence of IL-12 with beads coated 
with costimulatory antibodies and HLA-B*2705 monomer or HLA-A*0201 monomer. 
As determined by tetramer analysis, stimulation with HLA-B*2705 monomer coated 
mircrospheres led to specific cytotoxic T cell generation with corresponding specificity 
(Figure 1, left panel). No staining was observed with an irrelevant tetramer (Figure 1, 
right panel). Stimulations with artificial antigen presenting cells were highly effective 
as 55-80% of high density stimulated wells and 30-50% of low density stimulated 
cells were positive. No antigen-specific T cells were detected after ex vivo staining of 
PBMCs, consequently one can say that detected antigen specific T cells resulted 
from efficient in vitro priming. Therefore, MHC coated microspheres are useful tools 
for in vitro priming and expansion of antigen specific T cells. 
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Figure 1. Representative tetrameric analyses of bead stimulated CD8+ T cells. CD8+ T cells of 
two HLA-B*2705 and HLA-A*0201 positive donors were stimulated 3 times with artificial antigen 
presenting cells. Per donor, 30 wells with high density loaded beads and 30 wells with low density 
loaded beads were performed. Cells were stained with CD8-PerCP Ab, SRFGGAVVR (VEGF-114 to -106) 
tetramer-PE or irrelevant NLVPMVATV (HCMV pp65495-503) tetramer-APC (right panel). Percentage of 
tetramer+ cells within CD8+ T cell population is indicated in each plot. 
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Summary 
 
T cells are important effectors in the defense of human pathogens entering the 
organism. CD8+ T cells recognize peptides which are presented by MHC class I 
molecules and lyse cells which are infected by virus or intracellular pathogens. 
Moreover, they are able to destroy cancer cells. CD4+ T cells recognize peptides 
from exogenous proteins acquired by endocytosis or from internalized plasma 
membrane proteins which are presented on MHC class II. CD4+ T cells play an 
important role in the defense of bacteria and activation of the humoral immune 
response. 
The human cytomegalovirus (HCMV) is a cause of morbidity and mortality in 
immunocompromised persons. In contrast, in immunocompetent individuals HCMV is 
successfully controlled by specific CD8+ and CD4+ T cell responses. One aim of this 
thesis was the analysis of CD8+ and CD4+ T cell responses against HCMV to identify 
T cell epitopes which could be used for the development of a vaccine against the 
virus. Ex vivo analyses were performed with blood of healthy donors of different HLA-
types using recombinant peptide/MHC I complexes and/or intracellular cytokine 
staining to characterize T cell epitopes of HCMV. New T cell epitopes of several HLA 
restrictions could be identified. Furthermore, some were analysed with respect to 
immunodominant features and hierarchies among T cell epitopes identified. 
Furthermore, in vitro experiments were used to identify new T cell epitopes, e.g. 
stimulation of PBMCs from healthy donors with peptide loaded dendritic cells (DCs). 
Knowledge of T cell epitopes and their immundominant features can be useful for the 
generation of antigen-specific T cells for adoptive immunotherapy or for the 
development of a peptide-based vaccine against HCMV.  
A further aim of this thesis was the induction and analysis of CD8+ and CD4+ T cell 
responses against tumor-associated antigens. MHC class II ligands identified by 
mass spectrometric methods were used to perform in vitro stimulations. For CD8+ T 
cell stimulation, artificial antigen presenting cells (aAPCs) were used, for generation 
of antigen specific CD4+ T cells, DCs were loaded with peptides and used as APCs. 
Several new helper T cell epitopes from different tumor-associated antigens were 
identified.  
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Zusammenfassung 
 
Zur Abwehr humanpathogener Organismen sind T-Zellen unerlässlich. CD8+ T-Zellen 
erkennen Peptide, die auf MHC Klasse I präsentiert werden und stellen 
Abwehrreaktionen gegen Viren und intrazelluläre Erreger, aber auch gegen Krebs, 
bereit. CD4+ T-Zellen erkennen MHC Klasse II-präsentierte Peptide, die aus dem 
Inneren von Vesikeln stammen und spielen somit eine Rolle bei der Abwehr von 
Bakterien, aber auch bei der Anregung des humoralen Immunsystems über 
Aktivierung von B-Zellen. 
Das humane Cytomegalievirus (HCMV) verursacht bei Patienten mit geschädigtem 
oder nicht voll ausgebildetem Immunsystem häufig schwere bis tödlich verlaufende 
Infektionen. Bei immunkompetenten Individuen hingegen wird das Virus erfolgreich 
durch spezifische CD8+ und CD4+ T-Zellen kontrolliert. Ein Ziel dieser Arbeit war es, 
CD8+ und CD4+ T-Zellantworten gegen das humane Cytomegalievirus (HCMV) zu 
untersuchen, um T-Zellepitope für mögliche Impfstoffe zu identifizieren. Zur 
Charakterisierung von T-Zellepitopen aus HCMV wurden zum einen ex vivo-
Analysen in gesunden Spendern verschiedener HLA-Typisierung unter Verwendung 
rekombinanter Peptid/MHC I-Komplexe oder intrazellulärer Zytokinfärbung 
durchgeführt. Neue T-Zellepitope zahlreicher HLA-Restriktionen konnten identifiziert 
werden. Einige wurden zusätzlich hinsichtlich ihrer Immundominanz oder Hierarchie 
untereinander beleuchtet. Auch in vitro-Experimente, beipielsweise die Stimulation 
von gesunden Spender-PBMCs mit Peptid-beladenen dendritischen Zellen (DCs), 
trugen zur Identifizierung neuer T-Zellepitope bei. Dieses Wissen um T-Zellepitope 
und ihre immundominanten Eigenschaften kann nützlich sein für die Generierung 
antigen-spezifischer T-Zellen für adoptive Immuntherapien oder für die Entwicklung 
einer Peptid-basierenden HCMV-Vakzine. 
Neben viralen T-Zellantworten war ebenso die Induktion und Analyse von CD8+ und 
CD4+ T-Zellantworten gegen tumorassoziierte Antigene Bestandteil dieser Arbeit. 
Mittels massenspektrometrischer Verfahren identifizierte MHC Klasse II-Liganden 
wurden für in vitro Stimulationen eingesetzt. Artifizielle Antigen-präsentierende Zellen 
wurden als Werkzeuge für die Stimulation von Antigen-spezifischen CD8+ T-Zellen 
genutzt, während CD4+ T-Zellen mittels Peptid-beladener dendritischer Zellen 
stimuliert wurden. Dies führte zur Identifizierung neuer T-Zellepitope aus 
verschiedenen Tumor-assoziierten Antigenen. 
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Abbrevations 
 
aAPC artificial antigen presenting cell HIV human immunodeficiency virus 
Ab antibody HLA human leukocyte antigen 
APC allophycocyanin IFN interferon 
APC antigen presenting cell Ig immunglobulin 
BIRC5 Baculoviral IAP repeat-containing 5 IGFBP3 insulin-like growth factor binding 
protein 3 
BrdU 5-bromo-2´deoxyuridine IL interleukin 
β2m beta-2-microglobulin LCL lymphoblastoid cell line 
BSA bovine serum albumin MACS magnetically activated cell sorting 
CCA colon carcinoma MHC major histocompatibility complex 
CCND1 Cyclin D1 MMP7 matrix metallo proteinase 7 
CD cluster of differentiation NK natural killer cell 
CFSE carboxyfluorescein diacetate, 
succinimidyl ester 
PAMP pathogen-associated molecular 
pattern 
Cr chromium PBMC peripheral blood mononuclear cell 
CRA 51chromium release assay PBS phosphate buffered saline 
CTL cytotoxic T lymphocyte PCR polymerase chain reaction 
DC dendritic cell PE phycoerythrin 
DMSO dimethylsulfoxid PerCP peridinin chlorophyll protein 
complex 
DNA desoxyribonucleic acid PHA phytohaemagglutinin 
EBV epstein barr virus PMA phorbol myristate acetate 
EDTA ethylendiaminetetraacetic acid qRT-PCR quantitative reverse transcriptase-
PCR 
ELISA enzyme linked immunosorbent assay RCC renal cell carcinoma 
ELISpot enzyme linked immunospot assay RNA ribonucleic acid 
ER endoplasmic reticulum RPMI roswell park memorial institute 
FACS fluorescence activated cell sorting RT room temperature 
FCS fetal calf serum TAA tumor associated antigen 
FITC fluorescein isothiocyanate TAP transporter associated with 
antigen processing 
GFP green fluorescence protein TCR t cell receptor 
HCMV human cytomegalovirus TEMRA CD45+ effector memory T cells 
HD high density TNF tumor necrosis factor 
HEPES 4-(2-Hydroxyethyl)-piperazine-1-
ethanesulfonacid 
VEGF vascular endothelial growth factor 
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